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ABSTRACT 
    In adaptive design clinical trials, an endpoint at the final analysis that takes a long time 
to observe is not feasible to be used for making decisions at the interim analysis.  For 
example, overall survival (OS) in oncology trials usually cannot be used to make interim 
decisions. However, biomarkers correlated to the final clinical endpoint can be used.  
Hence, considerable interest has been drawn towards the biomarker informed adaptive 
clinical trial designs. 
    Shun et al. (2008) proposed a “biomarker informed two-stage winner design” with 2 
active treatment arms and a control arm, and proposed a normal approximation method to 
preserve type I error. However, their method cannot be extended to designs with more 
than 2 active treatment arms. In this dissertation, we propose a novel statistical approach 
for biomarker informed two-stage winner design that can accommodate multiple active 
arms and control type I error. We further propose another biomarker informed adaptive 
design called “biomarker informed add-arm design for unimodal response”. This design 
utilizes existing knowledge about the shape of dose-response relationship to optimize the 
procedure of selecting best candidate treatment for a larger trial. The key element of the 
proposed design is that, some inferior treatments do not need to be explored and the 
  vii 
design is shown to be more efficient than biomarker informed two-stage winner design 
mathematically. 
    Another important component in the study of biomarker informed adaptive designs is 
to model the relationship between the two endpoints. The conventional approach uses a 
one-level correlation model, which might be inappropriate if there is no solid historical 
knowledge of the two endpoints. A two-level correlation model is developed in this 
dissertation. In the new model a new variable that describes the mean level correlation is 
developed, so that the uncertainty of the historical knowledge could be more accurately 
reflected. We use this new model to study the “biomarker informed two-stage winner 
design” and the “biomarker informed add-arm design for unimodal response”. We show 
the new proposed model performs better than conventional model via simulations.  
    The concordance of inference based on biomarker and primary endpoint is further 
studied in a real case. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Conventional Adaptive Clinical Trial Designs  
The cost of drug development has increased dramatically in recent years. According to 
the NIH Office of Budget (Figure 1.1), the investment in pharmaceutical research and 
development has more than doubled in the past decade. However, the success rate for 
new drug applications (NDAs) remains low. As reported by the U.S. Government 
Accountability Office (GAO), the approval rate for NDAs submitted to the FDA in 2009 
is only about 40%.  
 
Figure 1.1 Pharma R&D Spending: 1995-2009 
 
Reasons for this include (Woodcock, 2005): 
 a diminished margin for improvement has escalated the level of difficulty in 
proving drug benefits;  
 genomics and other new science have not yet reached their full potential; 
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 mergers and other business arrangements have decreased candidates;  
 easy targets are more difficult to study;  
 rapidly escalating costs and complexity have decreased willingness to bring many 
candidates forward into the clinic.  
 
To improve clinical development, great efforts have been made to develop innovative 
approaches, especially on adaptive designs, which allow adaptations or modifications to 
aspects of the trial after its initiation without undermining the validity and integrity of the 
trial (Chang, 2005). The PhRMA Working Group defines an adaptive design as a clinical 
study design that uses accumulating data to direct modification of aspects of the study as 
it continues, without undermining the validity and integrity of the trial (Gallo, et al., 
2006).  
Commonly employed adaptive designs in clinical trials use the same study endpoint at 
the interim and final stages of a trial. These designs are called “conventional adaptive 
clinical trial designs”, which include, but are not limited to:  
 group sequential design;  
 sample-size re-estimation design; 
 drop-the-loser design;  
 add-arm design for unimodal response;  
 adaptive randomization design;  
 adaptive dose-finding design;  
 biomarker-adaptive design;  
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 adaptive treatment-switching design;  
 Bayesian adaptive design. 
 
1.1.1 Group Sequential Design  
A group sequential design (GSD) is an adaptive design that allows for premature 
termination of a trial due to efficacy or futility, based on the results of interim analyses 
(Chang, 2008). Basically, there are three different types of GSDs: early efficacy stopping 
design, early futility stopping design, and early efficacy/futility stopping design.  
The design typically leads to savings in sample size, time, and cost when compared with 
a classical design with a fixed sample size. For a trial with a positive result, early 
stopping ensures that a new drug product can be exploited sooner. If a negative result is 
indicated, early stopping avoids wasting resources. 
Different statistical methods have been proposed to avoid an inflation of the type I error 
rate of GSDs. Pocock (1977), O’Brien and Fleming (1979), and Wang and Tsiatis (1987) 
proposed critical values for the test statistic at each stage. These critical values were 
made for two-sided tests. The one-sided versions were proposed by DeMets and Ware 
(1980), DeMets and Ware (1982) and Pampallona and Tsiatis (1994). Lan and DeMets 
(1983) significantly increased the flexibility of the group sequential concept by 
introducing the alpha-spending function (or error spending function) approach, based on 
the research of Slud and Wei (1982). Lan and DeMets (1983) presented closed form 
spending functions that approximate the designs of Pocock (1977) and O’Brien and 
Fleming (1979) in the case of equal stage sizes. More flexible families of spending 
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functions were proposed by Kim and DeMets (1987) and Hwang, Shih and DeCani 
(1990). Tsiatis and Robins (1997) developed a very general formulation of a group-
sequential procedure based on the statistical information available at the times of the 
interim analyses. This “information-based design and monitoring procedure” can be 
applied to any type of model provided that there is a unique parameter of interest that can 
be efficiently tested. Applications were given, for example, by Mehta and Tsiatis (2001). 
In FDA guidance for industry regarding adaptive design clinical trials for drugs and 
biologics, group sequential design is categorized as a well-understood adaptive approach. 
 
1.1.2 Sample-Size Re-estimation Design 
The sample size requirement for a trial is sensitive to the treatment effect and its 
variability. An inaccurate estimation of the effect size and its variability could lead to an 
underpowered or overpowered design. In practice, it is often difficult to estimate the 
effect size and variability because of many uncertainties during protocol development. 
Thus, it is desirable to have the flexibility to re-estimate the sample-size in the middle of 
the trial. 
A sample-size re-estimation (SSR) design refers to an adaptive design that allows for 
sample-size adjustment or re-estimation based on the review of interim analysis results. 
There are two types of sample-size re-estimation procedures: sample-size re-estimation 
based on blinded data and sample-size re-estimation based on un-blinded data.  
For sample-size re-estimation based on blinded data, the sample adjustment is based on 
the observed pooled variance at the interim analysis to recalculate the required sample 
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size, which does not require un-blinding the data. Type I error adjustment is practically 
negligible in this scenario. Gould and Shih (1992) and Friede and Kieser (2001) 
presented the methods. The sample-size re-estimation based on blinded data is 
categorized as a well-understood adaptive approach in FDA guidance for industry 
regarding adaptive design clinical trials for drugs and biologics. 
For sample-size re-estimation based on un-blinded data, the effect size and its variability 
are re-assessed at interim stages, and sample size is adjusted based on the updated 
information. The type I error rate might be inflated in this scenario. Wittes, et al.(1999), 
Zucker, et al. (1999), Coffey and Muller (2001), and Denne and Jennison (1999) 
investigated internal pilot studies for this scenario with continuous data; Herson, et al. 
(1993), and Jennison, et al. (2003) discussed the scenario for binary data. Combination 
tests were proposed for Type I error control. Proschan and Hunsberger (1995) and Liu 
and Chi (2001) utilized conditional error functions; Lehmacher and Wassmer (1999) used 
inverse normal method; and Fisher (1998) introduced variance spending method. Chen, 
DeMets and Lan (2004) showed that if increasing sample size when the conditional 
power is greater than 50% at the interim, the regular unweighted test statistic can still be 
used without inflating the type I error rate. Gao, et al. (2008) used Brownian motion to 
derive a method of sample size re-estimation that achieves specified power against an 
alternative hypothesis corresponding to the current point estimate of the treatment effect. 
The sample-size re-estimation based on un-blinded data is categorized as less well-
understood adaptive approach in FDA guidance for industry regarding adaptive design 
clinical trials for drugs and biologics. 
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1.1.3 Drop-the-Loser Design 
 A drop-the-loser design is a design that allows dropping the inferior treatment groups 
(Chow and Chang, 2008). It is useful in phase II or phase II/III clinical development 
especially when there are uncertainties regarding dose levels. In drop-the-loser design, 
dose groups that are dropped may contain valuable information regarding dose response 
of the treatment under study. Therefore, the selection criteria and decision rules play 
important roles in the design. Ivanova (2003), Sun, et al (2006), Li, et al (2009), Wu and 
Zhao (2012) proposed drop-the-loser designs with different selection criteria. 
Typically, a drop-the-loser design is a two-stage design with one best arm retained. This 
type of design is also called “two-stage winner design” (Figure 1.2). A two-stage winner 
design starts with several active treatment arms and a control arm. At interim, the inferior 
arms will be terminated based on pre-specified criteria, and only the most promising 
treatment (“winner”) will be carried until the end of the study. The final comparison 
between the winner arm and the control arm will be performed on data from both stages 
and on study primary endpoint. Notice that the treatment arms in this design can be 
different dose levels or different combinations of compounds. 
Sampson and Sill (2005) discussed drop-the-loser design with a normal study endpoint, 
Sill and Sampson (2009) discussed the design with a binomial endpoint. Posch (2010) 
studied the type I error rate control for the design; Wu, S.S. (2010), and Neal, et al. 
(2011) investigated the interval estimations for drop-the-loser designs. 
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Figure 1.2 Two-Stage Winner Design 
 
1.1.4 Add-Arm Design for Unimodal Response 
Inspired by the features of drop-the-loser design, an effective 3-stage dose-finding design 
that allows adding arms at the interim (“Add-arm design for unimodal response”) was 
proposed (Chang and Wang, 2012). This design shows benefits when the dose-response 
curve is unimodal.  
The design starts with two arms; depending on the response of the two arms at the interim 
analysis and the assumption of unimodality, a decision on which new arm(s) to be added 
for the next stage is made. The added arm(s) will be compared with the winner arm from 
the first stage to decide which arm will be further carried to the end of the study. In this 
design, to find the best response treatment, not every treatment has to be explored; the 
key idea is that some inferior arms do not need to be exposed at all. 
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Type I error rate control and power were studied for the add-arm design. It’s shown that 
on average, the add-arm design is more powerful than the corresponding 2-stage drop-
the-loser design. It saves sample size from drop-the-loser design by as much as 20%.  
 
1.1.5 Other Designs 
Other conventional adaptive clinical trial designs include adaptive randomization design 
(ARD), adaptive dose-finding design, adaptive treatment-switching design, and Bayesian 
adaptive design. 
An adaptive randomization design is a design that allows modification of randomization 
schedules during the trial. One type of ARD is called response-adaptive randomization 
(RAR), in which the allocation probability is based on the response of the previous 
patients. Other adaptive randomization designs include treatment-adaptive 
randomization, and utility-adaptive randomization. 
An adaptive dose-finding (or “dose-escalation”) design is a design at which the dose level 
used to treat the next-entered patient is dependent on the toxicity of the previous patients, 
based on traditional escalation rules. More advanced dose-escalation rules have also been 
proposed recently, using modeling approaches (frequentist or Bayesian framework) such 
as the continual reassessment method (CRM) (O’Quigley, et al. 1990). The adaptive 
dose-finding design can reduce the sample size and overall toxicity in a trial and improve 
the accuracy and precision of the estimation of maximum tolerated dose (MTD). 
An adaptive treatment-switching design (ATSD) is a design that allows the investigator 
to switch a patient’s treatment from its initial assignment if there is evidence of lack of 
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efficacy or a safety concern. Despite allowing an alteration in treatment, many clinical 
studies are designed to compare the test treatment with the active control agent as if no 
patients had ever been switched.  
Bayesian approaches can be used in designing clinical trials for each phase. These 
adaptive designs are referred to “Bayesian Adaptive Design”. For example, a well-known 
Bayesian model-based phase I approach is continual reassessment method (CRM). Thall 
and Simon (1994) and Thall, Simon, and Estey (1995) introduced a class of phase II 
Bayesian clinical trial designs that include stopping rules based on decision boundaries 
for clinically meaningful events. Bayesian methods such as adaptive sample size using 
posterior probabilities and futility analyses using predictive probabilities can be used in 
confirmatory trials.  
 
1.2 Biomarker Informed Adaptive Clinical Trial Designs 
Clinical trials using conventional adaptive designs may increase the probability of 
success, reduce the cost and time for the drug candidate to market, and deliver the right 
drug to the right patient. However, the benefits of such designs might be limited if 
collecting measurements of primary clinical endpoint at interim takes too long. Take the 
oncology trials as an example: it usually takes 12 to 24 months to observe overall 
survival – the most commonly used and preferred regulatory primary endpoint. The 
extensive time needed to reach the interim analyses can present potential operational 
challenges (Gallo, 2006) and may delay bringing a drug to the market. 
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Recently, considerable interest has been drawn towards the biomarker informed adaptive 
clinical trial designs. A biomarker, or biological marker, refers to a measured 
characteristic which may be used as an indicator of the clinical measurements of disease 
process. That is, a short-term endpoint that is indicative of the primary clinical endpoint. 
Take the oncology trials as an example, the possible interim biomarker for overall 
survival (OS) could be: tumor size change (TSC), progression free survival (PFS), or 
overall response rate (ORR). 
The biomarker informed adaptive clinical trial designs incorporate biomarker information 
at the interim stages of the study for the decisions for interim adaptation. The decisions 
can be made based upon the biomarker only or on the available joint information of the 
biomarker and the primary clinical endpoint. Friede, et al.(2011), and Liu and Pledge 
(2005) discussed cases where only biomarker information is used for the interim 
decisions. Todd and Stallard (2005), Stallard (2010) studied situations when information 
for both biomarker and primary endpoint is used in interim analyses.  
In this dissertation, we will mainly focus on two types of biomarker informed adaptive 
clinical trial designs: the biomarker informed two-stage winner design and the biomarker 
informed add-arm design for unimodal response. Our discussions include the study 
design, statistical modeling, parameter estimation, error control, power evaluation and 
concordance analysis of the biomarker informed adaptive clinical trials. 
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 1.2.1 Biomarker Informed Two-Stage Winner Design 
Biomarker informed two-stage winner design was proposed and studied in Shun et 
al.(2008). Figure 1.3 shows a sketch of this design. It starts with several active treatment 
arms and a control arm. At interim, the inferior arms will be terminated based upon 
results for biomarker, and only the most promising treatment (“winner”) will be retained 
and carried to the end of the study with the control arm. The final comparison between 
the winner arm and the control arm will be performed on data from both stages and on 
study primary endpoint. The difference between this design and the conventional two-
stage winner design is that the interim decision is based upon the biomarker. 
Shun et al. (2008) studied the biomarker informed two-stage winner design with two 
active treatment arms and a control arm. They proposed a normal approximation for the 
distribution of the final test statistic of the design in order to preserve the type I error rate. 
However, their procedure cannot be extended to the design with more active treatment 
arms. In this dissertation, we will extend their work, and propose a novel statistical 
approach for type I error control of the biomarker informed two-stage winner design. Our 
method works for the design with any number of treatment arms. 
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Figure 1.3 Biomarker Informed Two-Stage Winner Design 
 
1.2.2 Biomarker Informed Add-Arm Design for Unimodal Response  
A new biomarker informed adaptive clinical trial design - “biomarker informed add-arm 
design for unimodal response” - will be proposed in this dissertation. The new design 
extends the idea of the add-arm design we proposed earlier (Chang and Wang, 2012). It 
utilizes the biomarker for early decisions on interim adaptation and the existing 
knowledge about the dose-response relationship to optimize the procedure of selecting 
best candidate treatment. The key element of this design is that, some inferior treatments 
could be identified, and do not need to be explored. This design is shown to be more 
efficient than a corresponding biomarker informed two-stage winner design via 
simulations. 
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1.3 Structure of the Dissertation 
This dissertation develops novel statistical methods for biomarker informed adaptive 
clinical trial designs.  
In Chapter 2, we propose a novel statistical approach for type I error control of the 
biomarker informed two-stage winner design. We use the idea of adjusting critical 
rejection values of the final test statistic of the design for preserving the type I error rate. 
The exact distribution of the final test statistic is derived and R functions for calculating 
the adjusted critical rejection values from the skewed distribution are developed. Our 
proposed method can work for the design with any number of treatment arms, which 
overcomes the limitation of the normal approximation method proposed by Shun et al. 
(2008). The critical rejection values associated with one-sided type I error rate 0.025 
(      ) for biomarker informed two-stage winner design with up to 7 active treatment 
groups are tabulated for easy reference. 
In Chapter 3, we develop a new two-level correlation approach to model the two 
endpoints in a biomarker informed adaptive design. A new variable that describes the 
mean level correlation is incorporated in the model. Compared with the conventional 
model which only considers the individual level correlation, the new model could reflect 
the uncertainty of the historical knowledge more accurately. We illustrate the new model 
in the context of the biomarker informed two-stage winner design. The type I error 
control, power performance and parameter estimation of the design using the new model 
are discussed mathematically and via simulations. Our proposed two-level correlation 
model is shown to perform better than the conventional model. 
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In Chapter 4, we propose a new biomarker informed adaptive design called “biomarker 
informed add-arm design for unimodal response”. This design contributes to optimizing 
the procedure of dose-finding when a biomarker of the primary clinical endpoint exists 
and previous evidence indicates a unimodal dose-response relationship. One of the major 
advantages of the proposed design is that some inferior treatments could be identified and 
do not need to be explored. Consequently, the proposed design may further reduce the 
expected sample size while gaining information about the effective dose more quickly.  
We study the design using the two-level correlation model proposed in Chapter 3 and 
carry out extensive simulation studies to compare this design against the corresponding 
biomarker informed two-stage winner design in a variety of settings. The new design is 
shown to improve the efficiency of a clinical trial. 
The discussions in Chapter 2, 3, 4 are within a theoretical framework built on the 
distributions of the biomarker and primary clinical endpoint without specifying an exact 
regression model linking the two endpoints. In Chapter 5, we further study a realistic case 
in non-small cell lung cancer when a model linking the two endpoints (tumor size change 
and overall survival) has been established. We investigate the factors that influence the 
concordance of decisions made based on tumor size change and overall survival. This 
study helps us better understand the profit and loss of using a biomarker for interim 
decisions. 
We provide concluding remarks and discuss the possibility of using a biomarker 
informed adaptive design in a late phase confirmatory trial in Chapter 6. 
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CHAPTER 2  
FINDING CRITICAL VALUES WITH CONTROLLED TYPE I ERROR FOR A 
BIOMARKER INFORMED TWO-STAGE WINNER DESIGN 
 
2.1 Motivation 
As sponsors recognize its value and regulators come on board, adaptive clinical trial 
designs are growing in popularity in recent years. Adaptive trial designs use 
accumulating data to allow sponsors to adjust parameters for ongoing clinical trials, 
including dosage, subject population or sample size. Based on adaptations applied, 
adaptive designs can be classified into three categories: prospective, concurrent and 
retrospective adaptive designs (Chow and Chang, 2008). Prospective adaptations (also 
known as design adaptations) imply that need for such adaptations are envisioned and 
approved in the protocol at the beginning of the trial. On the contrary, concurrent 
adaptations (also known as ad-hoc adaptation) imply changes that could not be 
envisioned at the beginning, but their need became apparent as trial continues. 
Retrospective adaptations generally imply changes in statistical analysis plan made prior 
to database lock or un-blinding. The use of adaptive designs can be seen to accelerate 
clinical development and improve efficiency.  
General concerns with using adaptive designs in drug development as listed in FDA's 
draft guidance on adaptive design in clinical trials are as follows: 
A. Potential to increase the chance of erroneous positive conclusions and of positive 
study results that are difficult to interpret 
1. Bias associated with the multiplicity of options 
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2. Difficulty in interpreting results when a treatment effect is shown 
3. Operational bias 
B. Potential for counterproductive impacts of adaptive design 
1. Potential to limit identifying gaps in knowledge 
2. Elimination of time to thoughtfully explore study results 
C. Complex adaptive designs – potential for increased planning and more advanced 
time frame for planning 
From statistical point of view, adaptations to trial and/or statistical procedures could 
introduce bias/variation to data collection, result in a shift in location and scale of the 
target patient population, and lead to inconsistency between hypotheses to be tested and 
the corresponding statistical tests. 
These concerns will not only have an impact on the accuracy and reliability of statistical 
inference drawn on the treatment effect, but also present challenges for development of 
appropriate statistical methodology for an unbiased and fair assessment of the treatment 
effect. One of these challenges is to preserve the overall type I error rate for adaptive 
clinical trials at pre-specified level of significance.  
A variety of approaches have been proposed over the past decade for preventing type I 
error inflation, some of which have generated a great deal of attention, accounting for 
much of the recent interest in adaptive designs. These adjustment approaches include: 
error spending approach for classical group sequential plans (Pocock 1977, O’Brien and 
Fleming 1979, Lan and DeMets 1983); Combination of p-values, such as Fisher’s 
combination test (Bauer 1989, Bauer and Kohne, 1994), Inverse Normal Method 
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(Lehmacher and Wassmer 1999), sum of p-values approach (Chang 2008); conditional 
error function (Proschan and Hunsberger 1995, Liu and Chi 2001 Muller and Shafer 
2001); fixed weighting method (Cui, Hung and Wang 1999); variance spending method 
(Fisher 1998, Shen and Fisher 1999); and multiple testing methodology such as closed 
test procedures (Bretz, et al. 2006, Holm 1979, Hochberg 1988, Hommel 1988). These 
methods work for conventional adaptive designs that use the same study endpoint at the 
interim and the final stages of the study. 
Considerable interest has been drawn towards the biomarker informed adaptive clinical 
trial designs recently. These designs make interim decisions based upon inference on a 
biomarker, which is a short-term endpoint that is indicative of the primary endpoint, and 
hence have the potential to prevent certain operational challenges and to bring a drug to 
market faster. To prevent type I error inflation for biomarker informed adaptive trials, 
Todd and Stallard (2005) presented a method for group sequential trials for which the 
interim treatment selections are based upon the biomarker only. Stallard (2010) proposed 
a method for group sequential trials that use both the available biomarker and primary 
endpoint information for treatment selections. Their method controls the type I error rate 
in the strong sense. Friede et al. (2011) considered a biomarker informed drop-the-losers 
design, they brought together combination tests for adaptive designs and the closure 
principle for multiple testing, and achieved control of the family-wise type I error rate in 
the strong sense. Scala and Glimm (2011) discussed a method for the biomarker informed 
adaptive designs when the endpoints are time-to-event data. Jenkins et al. (2010) 
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presented an approach for a biomarker informed group sequential enrichment design with 
time-to-event endpoints. 
Shun, Lan and Soo (2008) studied a biomarker informed two-stage winner design, where 
interim decision is made by ranking of the observed effects of biomarker, they derived 
the unconditional distribution of the final test statistic for the design with two active 
treatment arms and one control arm, and proposed its normal approximation for 
calculation of the critical value to preserve type I error rate. However, the proposed 
normal approximation procedure cannot be extended to designs with more active 
treatment groups. In this chapter, we propose a novel statistical approach for biomarker 
informed two-stage winner design that can accommodate multiple active arms and 
control type I error. We use the idea of adjusting critical rejection values of the final test 
statistic of the design for preserving the type I error rate. The exact distribution of the 
final test statistic is derived and R functions for calculating the adjusted critical rejection 
values from the skewed distribution are developed. The critical rejection values 
associated with one-sided type I error rate 0.025 for biomarker informed two-stage 
winner design with up to 7 active treatment groups are tabulated for easy reference. 
What makes a biomarker informed adaptive design special is that, two endpoints are 
involved in the design: the biomarker and the study primary endpoint. Therefore, the 
model used to describe the relationship between the two endpoints plays a role for 
evaluation of the design. Shun et al. (2008) used the conventional approach to model the 
two endpoints in a biomarker informed two-stage winner design. Wang, Chang and 
Menon (2013) proposed a two-level correlation model to describe the relationship 
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between the two endpoints, which turns to be more appropriate compared with the 
conventional model. In this chapter, both models will be considered in our discussion for 
finding critical rejection values for final test statistic to preserve type I error rate. 
 
2.2 Finding Critical Rejection Values for Final Test Statistic in Biomarker 
Informed Two-Stage Winner Design 
2.2.1 Biomarker Informed Two-Stage Winner Design 
A biomarker informed two-stage winner design is a design that combines a phase II and a 
phase III study. It starts with several active treatment arms and a control arm with a 
planned interim analysis on biomarker. At interim, the inferior arms will be terminated 
based on ranking of the observed effects of biomarker, and only the most promising 
treatment (“winner”) will be carried till the end of the study with the control arm. The 
final comparison between the winner arm and the control arm will be performed on data 
from both stages and on study primary endpoint. This design has the potential to shorten 
the duration of the trial for drug development and avoid unnecessary waste of resources. 
Let   be number of treatment groups (    active treatment groups, and 1 control 
group), and   be the maximum sample size for each treatment group. Assume the interim 
analysis is planned at the information time   
  
 
, where    is the interim sample size 
(     . Two sets of measurements are obtained: {  
   
         }, the 
measurements of the biomarker at interim stage for  th person in  th treatment group; and 
{  
   
        }, the measurements of the study primary endpoint at final stage for  th 
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person in  th treatment group.            .     represents the control group and 
          the active treatment groups.   
Let    
   ̅̅ ̅̅ ̅
 
 
  
∑  
   
 be the mean of the biomarker measurements for treatment group   at 
interim, and   
   ̅̅ ̅̅ ̅
 
 
 
∑  
   
 be the mean of the primary endpoint measurements for 
treatment group   at final. The decision rule of the winner design is that, if the interim 
observations    
   ̅̅ ̅̅ ̅
     (   
   ̅̅ ̅̅ ̅       
     ̅̅ ̅̅ ̅̅ ̅̅ ), select treatment   as the effctive treatment, 
and carry only treatment group   and the control group to the end of the study. The option 
that more than one treatment groups will be kept when the interim outcomes are almost 
the same is not considered, because either treatment group can be selected in this 
situation. The final assessment will be based on the study primary endpoint   comparing 
the selected treatment group   and the control group. 
 
2.2.2 The Two Models for Fitting the Two Endpoints 
In this section, we briefly review two commonly used techniques for modeling the two 
endpoints (i.e., the biomarker and the study primary endpoint) in a biomarker informed 
two-stage winner design. The first is the conventional approach, which uses the 
individual-level correlation   to describe the relationship between the biomarker and the 
primary endpoint. The other is the two-level correlation model proposed by Wang, et al. 
(2013). This model considers both the individual-level and mean-level correlation 
between the biomarker and the primary endpoint. 
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We assume both the biomarker and the primary endpoint are normally distributed in the 
design. Let   
  be the mean of biomarker for treatment group  ,   
  be the variance. For a 
fixed  , assume {  
   
         }        , and   
   
  (  
    
 ). Denote the 
standardized mean of biomarker for each treatment group by   
  ,   
   
  
 
  
 . 
Let   
  be the mean of study primary endpoint for treatment group  ,   
  be the variance. 
For a fixed  , assume {  
           }         , and   
   
  (  
    
 ). Denote the 
standardized mean of study primary endpoint for treatment group   by   
   
  
 
  
 .  
Assume also that {  
   
         } and {  
   
         } are correlated with a 
correlation ρ for the same   and  , that is              . 
Since both endpoints are assumed to be normally distributed, the conventional approach 
uses a multivariate normal distribution with a correlation coefficient ρ for modeling the 
relationship between the biomarker and primary endpoint: 
(
  
   
  
   
)  ((
  
 
  
 )  (
  
      
       
 ))             . 
This approach was used for modeling the two endpoints in the study of Shun et al. 
(2008), Li et al. (2010), etc. It has the limitation that the means for both endpoints have to 
be specified while running power simulation, which sometimes might cause problems if 
no solid historical knowledge is available. 
The two-level correlation model proposed by Wang et al. (2013) incorporated a new 
variable,   , into the model, which refers to the estimated mean level correlation between 
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the biomarker and the primary endpoint. The new variable, together with its distribution, 
would reflect the uncertainty about the mean-level relationship between the two 
endpoints due to a small sample size of historical data. 
Assume    is normally distributed and centered at   ,    
  
  
  
  , which is the true mean-
level correlation between the two endpoints. The two-level correlation model can be 
written as follows: 
(
  
   
  
  
   
  
   
)  ((
  
  
    
  )  (
  
  
))  
    (      
 ) ,                  . 
And the unconditional distribution of the model could be expressed as follows (see 
Chapter 3 for details): 
(
  
   
  
  
   
  
)  
(
 
 
(
  
  
  
  )  
(
 
  √(  
  )
 
   
   
 √(  
  )
 
   
   (  
  )
 
   
   )
 
)
 
 
,                
This model takes account of the uncertainty about the mean-level correlation, and have 
been shown to be more appropriate compared with the conventional model.  
Both of the two models will be considered in the next section when we derive the 
distribution of the final test statistic for the biomarker informed two-stage winner design. 
Designs with up to 7 active treatment arms will be studied.  
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2.2.3 Test Statistic and its Distribution 
To prevent type I error inflation of the biomarker informed two-stage winner design, we 
use the idea of adjusting critical rejection values of the final test statistic of the design. In 
this section, we derive the exact distribution of the final test statistic for the biomarker 
informed two-stage winner design under the conventional one-level correlation model, 
and the asymptotic distribution of the final test statistic under Wang, et al.’s two-level 
correlation model. As it is shown, this derivation approach works for biomarker informed 
two-stage winner designs that accommodate any number of active arms. 
Consider the following hypotheses:  
      
        
    
   
      
    
              
    
   
It is reasonable to assume that   
        
    
  when   
        
    
  and 
   . For simplicity, assume   
  is known. 
Let    be the test statistic comparing the primary endpoint of the  th treatment group and 
the control group.  
Under the conventional model, let  
   √
 
   
 (  
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)  
It could be shown that,  
    (
  
    
 
√   
 
 
  )  
and under   ,          . 
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Under the two-level correlation model proposed by Wang et al. (2013), let 
   √
 
  
  (  
  ̂ )
 
   
 ̂  (  
  ̂ )
 
   
 ̂    
(  
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)             
It could be shown that    is asymptotically normal,  
    (√
 
[(  
  )
 
   
  (  
  )
 
   
   ]
(  
     
  )  )  
And under   ,     is asymptotically standard normal. 
The final test statistic of the biomarker informed two-stage winner design can then be 
expressed as: 
     , if    
   ̅̅ ̅̅ ̅
     (   
   ̅̅ ̅̅ ̅      
     ̅̅ ̅̅ ̅̅ ̅̅ ̅)                 . 
That is, conditional on the interim selection,  takes on the value of the effect from the 
“winner” treatment group as the final test statistic.  
For the very general case under   ,  the distribution of the final test statistic  could be 
derived as: 
             ∑  (        
   ̅̅ ̅̅ ̅      (    
   ̅̅ ̅̅ ̅      
     ̅̅ ̅̅ ̅̅ ̅̅ ̅ ))        
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   ̅̅ ̅̅ ̅     
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Under the conventional model, 
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 is from a multivariate normal distribution. 
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More generally, for any value of        : 
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Under the two-level correlation model proposed by Wang et al. (2013), 
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Thus, for a biomarker informed two-stage winner design with        treatments, the 
distribution of final test statistic under the conventional model is: 
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And the distribution of final test statistic under the two-level correlation model is: 
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It can be seen that, the interim treatment selection of the design skewed the distribution of 
its final test statistic. Hence, appropriate statistical adjustment is necessary in order to 
preserve the type I error rate of the design. As the general distribution of the final test 
statistic is written, the type I error rate of the design can be preserved by adjusting the 
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critical rejection value for the final test statistic. In the following section, we focus our 
work on finding the adjusted critical rejection values for final test statistic. 
 
2.2.4 Critical Rejection Values and R 
Under   , the distribution of the final test statistic of a biomarker informed two-stage 
winner design with   treatments can be written as follows. 
Under conventional model: 
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Under the two-level correlation model proposed by Wang et al. (2013): 
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If    
     
         
 , that is the variability of the estimated mean-level correlation 
for each treatment group is the same, the above distribution can be approximated by: 
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Denote the distribution of final test statistic  under    by   . Let    be the upper      
percent quintile of   , 
     
             
         
The type I error rate of the design can be controlled at level α if the 1-sided rejection 
region is   {      }.  
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We develop R functions for calculating the critical rejection values    for biomarker 
informed two-stage winner design with up to 7 active treatment arms (Appendix A).  
R functions convention_cv_Kk (       ) are for calculating the integration of       
for biomarker informed two-stage winner design with     active treatment groups and 
a control group under conventional model and therefore can be used to find critical 
rejection values for the final test statistic. For example, to find the critical rejection value 
that preserves type I error rate at 0.025 for a biomarker informed two-stage winner design 
with 3 active treatment arms and a control arm, convention_cv_K4 can be used, and an 
output of 0.975 is expected for the critical rejection value. If the interim sample size of 
the design is 50, the maximum sample size per treatment group is 100, and      ,  
> convention_cv_K4(w=2.232, n1=50, N=100, rho=0.8, alpha=0.025) 
$p 
[1] 0.9750554 
attr(,"error") 
[1] 8.166802e-07 
attr(,"status") 
[1] "normal completion" 
$error 
[1] 5.54042e-05 
Thus, the critical rejection value          in this case. 
In some scenarios, the individual-level correlation   is unknown, the sample correlation 
coefficient  ̂ is suggested to be used for an approximate value of   . Simulations are 
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further suggested to be performed to ensure that the type I error rate of the design is 
preserved. 
R functions wang_cv_Kk (       ) are for calculating values for biomarker informed 
two-stage winner design with     active treatment groups and a control group under 
the two-level correlation model proposed by Wang et al (2013). These functions work in 
a similar way as functions convention_cv_Kk. If there are unknown parameters 
incorporated in the functions, the parameter estimates are suggested to be used for 
calculating an approximate critical rejection value. Further simulations are encouraged to 
ensure a preserved type I error rate.  
Table 2.1 – Table 2.5 provide the critical rejection values        for biomarker informed 
two-stage winner design with up to 7 active treatment group under conventional model. 
As expected, the critical rejection value        increases as ρ increases. It can also be 
seen that, the later the interim look, the larger the critical rejection value        need to 
be. Besides, the more active treatment groups included in the design, the larger the 
critical rejection value        have to be. 
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Table 2.1       for biomarker informed two-stage winner design (   ) 
  0 0.2 0.5 0.8 1 
1 0.3n N   
0.025w  1.96 2.023 2.108 2.182 2.225 
1 0.5n N   
0.025w  1.96 2.041 2.146 2.232 2.279 
1 0.8n N   
0.025w  1.96 2.061 2.186 2.281 2.328 
 
 
Table 2.2        for biomarker informed two-stage winner design (   ) 
  0 0.2 0.5 0.8 1 
1 0.3n N   
0.025w  1.96 2.038 2.142 2.232 2.286 
1 0.5n N   
0.025w  1.96 2.058 2.188 2.294 2.352 
1 0.8n N   
0.025w  1.96 2.083 2.237 2.356 2.415 
 
 
Table 2.3        for biomarker informed two-stage winner design (   ) 
  0 0.2 0.5 0.8 1 
1 0.3n N   
0.025w  1.96 2.048 2.165 2.27 2.33 
1 0.5n N   
0.025w  1.96 2.072 2.218 2.34 2.408 
1 0.8n N   
0.025w  1.96 2.1 2.275 2.411 2.48 
 
  
  
34 
Table 2.4        for biomarker informed two-stage winner design (   ) 
  0 0.2 0.5 0.8 1 
1 0.3n N   
0.025w  1.96 2.055 2.185 2.299 2.366 
1 0.5n N   
0.025w  1.96 2.082 2.242 2.376 2.452 
1 0.8n N   
0.025w  1.96 2.112 2.305 2.455 2.531 
 
 
Table 2.5        for biomarker informed two-stage winner design (   ) 
  0 0.2 0.5 0.8 1 
1 0.3n N   
0.025w  1.96 2.063 2.202 2.323 2.396 
1 0.5n N   
0.025w  1.96 2.091 2.262 2.407 2.488 
1 0.8n N   
0.025w  1.96 2.123 2.33 2.492 2.575 
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2.3 Discussion 
In this chapter, we have proposed a novel statistical approach for type I error control of 
the biomarker informed two-stage winner design. We use the idea of adjusting critical 
rejection values of the final test statistic of the design for preserving the type I error rate. 
We derive the exact distribution of the final test statistic for the biomarker informed two-
stage winner design under the conventional one-level correlation model, and the 
asymptotic distribution of the final test statistic under Wang et al.’s two-level correlation 
model, hence the critical rejection values    could be obtained through mathematical 
integration. We developed R functions for calculating the adjusted critical rejection 
values from the skewed distribution of final test statistic. As shown, the critical rejection 
value        increases as any of ρ,   
  
 
 increases.  
Our proposed method overcomes the limitation of the normal approximation method 
proposed by Shun et al. (2008), and works for designs with any number of treatment 
arms. However, it has the limitation that it works only for the biomarker informed two-
stage winner design with normal interim and final endpoints. For the designs with non-
normal endpoints, transformations might be used to convert the data to follow normal 
distribution. Developing novel approaches for type I error control for biomarker informed 
two-stage winner design with non-normal endpoints would be an interesting topic for 
future studies.  
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CHAPTER 3  
MODELING THE BIOMARKER INFORMED ADAPTIVE  
CLINICAL TRIAL DESIGNS 
 
3.1 Introduction 
The pharmaceutical industry has increased its commitment to personalized medicine as 
the cost of genetic sequencing declines. Personalized medicine aims to deliver the right 
drug to the right patient. In addition to discovering the right drug, finding the right dose 
and identifying the right patient, it is also desirable to shorten the time of drug 
development in order to bring the drug to the patient faster. Different clinical trial designs 
have been proposed for this purpose. One such design is a seamless phase II/III drop-the-
losers (or “pick-the-winner”) design, which has the potential to terminate the inferior 
treatment groups (i.e. the “losers”) early if no efficacy is shown. It minimizes “white 
space” between phase II and phase III of the studies, and efficiently uses all the patient 
data both in the learning and confirming phases. 
Statistical methods exist for controlling the type I error rate and constructing estimators 
for the drop-the-losers design. Stallard and Todd (2003), Kelly et. al. (2005), and Stallard 
and Friede (2008) proposed approaches for sequential trials; Bauer and Kieser (1999) 
considered the method of combining p-values from different stages; Sampson and Sill 
(2005) developed a uniformly most powerful conditionally unbiased test (UMPCU) for 
normally distributed data; Chang, Chow and Pong (2006) suggested the contrast test with 
a p-value combination method. 
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In drop-the-losers clinical trials, the same endpoint is used for both the interim and final 
analyses of the study. However, the benefits of such an approach could be limited if 
collecting measurements of primary clinical endpoint at interim takes very long. For 
example, in oncology trials, it usually takes 12 to 24 months to observe overall survival – 
the most commonly used and preferred regulatory primary endpoint. The extensive time 
needed to reach the interim analyses can present potential operational challenges (Gallo, 
2006) and may delay bringing a drug to the market. 
Considerable interest has been drawn towards the short-term endpoint (“biomarker”) 
informed adaptive seamless phase II/III designs. These designs incorporate biomarker 
information at the interim stages of the study. The decision(s) on interim adaptation can 
be made based upon the biomarker only or on the available joint information of the 
biomarker and the primary endpoint. 
Todd and Stallard (2005) presented a biomarker informed group sequential design for 
which the interim treatment selection is based upon a biomarker. Stallard (2010) studied a 
biomarker informed group sequential design that uses both the available biomarker and 
primary endpoint information for treatment selection. He proposed a method for the 
adjustment of the usual group sequential boundaries to maintain strong control of the 
family-wise type I error rate. Shun, Lan and Soo (2008) presented a biomarker informed 
two-stage winner design with two active treatments arms and a control arm. They derived 
the unconditional distribution of the final test statistic for the design and proposed a 
normal approximation approach for the final distribution to preserve the type I error rate. 
Liu and Pledger (2005), Li and Wang and Ouyang (2009), and Li, et al. (2009) 
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considered biomarker informed drop-the-losers designs where more than one treatment 
can be selected at the interim. Friede et al. (2011) proposed a type I error control 
procedure for biomarker informed drop-the-losers design. Their method brought together 
combination tests for adaptive designs and the closure principle for multiple testing, 
which combined p-values from hypothesis tests for primary endpoint. However, the 
correlation between the biomarker and primary endpoint was not considered in their 
approach while investigating type I error rate of the design. Scala and Glimm (2011) 
discussed application of the biomarker informed adaptive designs when the endpoints are 
time-to-event data. Jenkins et al. (2010) proposed a biomarker informed group sequential 
enrichment design with time-to-event endpoints, and methodology was presented which 
controls the type I error rate. 
Biomarker informed adaptive clinical trial designs have the potential to speed up drug 
discovery and shorten time to market. It could be very helpful for the development of 
personalized medicine, if the biomarker used at the interim is a good indicator of the 
primary clinical endpoint. 
 
3.2 Motivations and Concepts 
To conduct a drug trial that uses biomarker informed adaptive procedures, statistical 
simulations are suggested to be performed first in order to understand the operating 
characteristics, including sample size for a target power, of the design. An important 
component of this process is to specify a model for simulation of the two endpoints 
incorporated in the study. The conventional approach uses the one-level (“individual-
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level” only) correlation model, together with historical knowledge, to describe the 
relationship between the biomarker and primary endpoint. This approach can easily 
misestimate the power of a biomarker informed design if there is no well-established 
knowledge about how the biomarker and the primary endpoint are correlated. For 
example, when the rank order of mean responses of the biomarker for each treatment 
group is assumed to be the same as that of the primary endpoint based on historical 
observations, the power of a biomarker informed two-stage winner design is very 
possible to be overestimated by the conventional model, as the uncertainty of the 
historical knowledge has been ignored. In this case, the sample size suggested by 
simulation may lead to an underpowered trial. 
The approval rate for new drug applications (NDAs) submitted to the FDA recently is 
only about 40%. This fact indicates that there are plenty of trials that are underpowered. 
It is desirable to propose approaches that lead to a more accurate assessment of clinical 
trial designs. 
In this manuscript, we propose a two-level correlation model to fit the two endpoints in a 
biomarker informed adaptive design. This model considers not only the individual-level 
correlation between the biomarker and the primary endpoint, but also accounts for the 
variability of the estimated mean-level correlation (or “mean-level association”). The 
uncertainty due to a small sample size of historical data about the relationship between 
the two endpoints could be more accurately reflected in our model.  
The new model is illustrated in the context of a two-stage winner design with three active 
treatment arms and a control arm. We assume both the biomarker and primary endpoint 
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are normally distributed, and derive the asymptotic distribution of the final test statistic of 
the design using our new model. We further propose a statistical approach for type I error 
control of the design, and carry out extensive simulations to study the power performance 
of the design for different relationship between the biomarker and primary endpoint. It is 
shown that the new proposed model performs better than the conventional one-level 
correlation model. An approach for estimating the parameters incorporated in our new 
model is further proposed. 
Throughout this chapter, we want to deliver the message that the conventional one-level 
correlation model is not sufficient for modeling the relationship between the two 
endpoints in a biomarker informed adaptive design. The shape of mean-level correlation, 
as well as the uncertainty about the shape, need also be considered. 
 
3.3 Issues in Conventional One-Level Correlation Model 
The conventional one-level correlation model used for describing the relationship of the 
two endpoints in a biomarker informed adaptive design considers only the individual-
level correlation (ρ). 
For example in a biomarker informed adaptive clinical trial design, let {             } 
be measurements of interim endpoint, and {            } be measurements of primary 
endpoint, assume both endpoints are normally distributed, then the conventional approach 
will use the following multivariate normal distribution with a correlation coefficient ρ, to 
fit the two endpoints: 
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Hence if the conventional one-level correlation model is used in statistical simulations for 
biomarker informed trials, the means of the two endpoints have to be specified based on 
the historical knowledge (as shown in Li et al. 2009). In this way, if there is no well-
established historical knowledge about the two endpoints, the simulation study results 
might be inaccurate. For example, if only a small amount of historical data is available 
for the two endpoints in a biomarker informed two-stage winner trial, which indicates a 
same rank order of the mean responses of the two endpoints for each treatment group, 
then the power of this trial is very possible to be overestimated by the conventional 
model, as the uncertainty of the historical knowledge has been ignored. In addition, there 
would not be much difference in power between different values of correlation 
coefficient ρ between the two endpoints. 
Friede et al. (2011) pointed out that the effect of the individual level correlation ρ 
between the biomarker and primary endpoint on power is small if the means of biomarker 
in treatment groups are fixed and are different. In their paper, the authors showed (in 
Figure 2(a)) how the estimated power of a biomarker informed design has changed for 
different estimations of treatment difference in biomarker. As shown in their figure, there 
is almost no difference in the power of the design for different values of the correlation 
coefficient ρ. For example, when the estimated treatment difference in biomarker is 0.2, 
the estimated power of their design changes from around 83% to 85% as ρ increases from 
0 to 1. Li et al. (2009) also mentioned that the influence of ρ on power is really small 
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when compared to other factors. Their paper showed an increase in simulated power from 
70.5% to 73.7% as ρ increased from 0.2 to 0.8. We ran simulations for a two-stage 
winner design with a survival primary endpoint. The design was assumed to have 3 active 
treatment arms and 1 control arm, with fixed survival means 2.46, 3.32, 3 and 2.22 for 
each treatment arm respectively; and fixed biomarker log-means 1.6, 1.9, 1.8 and 1.5. 
The critical value for the final test statistic was obtained by simulation with the type I 
error rate at 0.05 level. Our simulation results (Table 3.1) are consistent with the previous 
findings. 
 
Table 3.1 Power Evaluation Using Conventional One-Level Correlation Model 
  censoring rate Interim size Max size power power with best-treatment 
0 0.2 90 270 94.0% 72.2% 
0.3 0.2 90 270 95.0% 72.8% 
0.5 0.2 90 270 95.8% 73.8% 
0.8 0.2 90 270 96.0% 73.6% 
 
It could be seen from Table 3.1 that if the conventional one-level correlation approach is 
used, when ρ increase from 0 to 0.8, the simulated power of the two-stage winner design 
changes from 94.0% to 96.0%. It is only slightly different. This finding violates the 
presumption that the design should have a better performance when ρ is large, as ρ is the 
only index in the conventional model to describe the correlation between the two 
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endpoints. In addition, the simulation results also suggest that the power is probably 
overestimated by the conventional one-level correlation model. 
 
Figure 3.1 Illustration of Relationship Between Biomarker and Primary Endpoint 
 
Figure 3.1 illustrates different cases where the individual level correlation ρ between the 
biomarker and primary endpoint is the same. Two different biomarkers are described in 
the figure, both of which are correlated with the primary endpoint with correlation 
coefficient      . Consider designs that use the two biomarkers at interim respectively: 
if the same treatment difference is found on biomarkers at interim, the power of the two 
designs might be different, since the treatment difference on the primary endpoint is 
different due to the different slope. Therefore, it’s not sufficient to describe the 
relationship between biomarker and primary endpoint by only considering the individual 
level correlation ρ. The slope, which is the rate of change of the primary endpoint with 
respect to biomarker, should also be incorporated. The conventional one-level correlation 
model does not incorporate the variability of the slope caused by the uncertainty of 
historical data, which might easily lead to misestimated power. 
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3.4 Biomarker Informed Two-Stage Winner Design with the Proposed Two-
Level Correlation Model  
We propose a two-level correlation model to describe the relationship between the two 
endpoints in a biomarker informed adaptive design, in order to obtain a more accurate 
assessment for the design. To illustrate the proposed model, we consider a biomarker 
informed two-stage winner design with 3 active treatment arms and a control arm.  
 
3.4.1 The Biomarker Informed Two-Stage Winner Design 
A biomarker informed two-stage winner design is a special biomarker informed drop-the-
losers design, where only a single active treatment will be selected for final evaluation. It 
combines a phase II and a phase III study, and starts with several active treatment arms 
and a control arm with a planned interim analysis. At the interim, the inferior treatments 
will be dropped based on observations of the biomarker, which is a short-term endpoint 
that is indicative of the primary endpoint. Only the most promising one will be retained 
and carried until the end of the study. The final comparison of winner treatment with 
control is performed on the data collected from both stages. This design could potentially 
shorten the duration of the development, and aid in delivering the medicine to the patient 
faster. 
For a biomarker informed two-stage winner design, Let {  
            } be 
measurements of biomarker at interim stage, and {  
           } be the measurements 
of primary endpoint obtained at final stage.    is the interim sample size per group, and 
  
45 
  is the maximum sample size for each treatment,     ;          . Let     
represents the control group and         the 3 active treatment groups.    
   ̅̅ ̅̅ ̅
 
 
  
∑  
   
 is the mean of the biomarker measurements for treatment group  , and   
   ̅̅ ̅̅ ̅
 
 
 
∑  
   
 is the mean of the primary endpoint measurements for treatment group  .  
The decision rule of the winner design is that, if the interim observations    
   ̅̅ ̅̅ ̅
 
    (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅), select treatment   as the effctive treatment, and carry only 
treatment group   and the control group to the end of the study. The option that more than 
one treatment groups will be kept when the interim outcomes are almost the same is not 
considered, because either treatment group can be selected in this situation. The final 
assessment will be based on the study primary endpoint   comparing the selected 
treatment group   and the control group. 
 
3.4.2 The Proposed Two-Level Correlation Model 
For simplicity, we assume both the biomarker and the primary endpoint are normally 
distributed in the biomarker informed two-stage winner design. The two-level correlation 
approach we proposed models the design in the following way: 
Assume,   
            , are standardized means of biomarker for treatment group  , 
and   
  is the common variance. For a fixed  , assume {  
            }        , and 
  
   
  
  (  
    ). 
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Assume {  
           }        , denote the true mean-level correlation between 
biomarker and primary endpoint by    for treatment group  . If    is known, the 
conditional distribution 
  
   
  
     (  
    ), where    
  
  
  
  . 
In reality, since the true mean-level correlation    is unknown, an estimate    is obtained 
from historical data to describe the estimated mean-level correlation. We assume 
           
  , and hence  
  
   
  
           
     .  
It is easy to show, under this setting, the unconditional distribution for the primary 
endpoint is: 
  
   
  
  (  
   (  
  )
 
   
   ). 
The individual level correlation between the biomarker and primary endpoint is denoted 
by ρ, where              . 
Thus, the conditional joint two-level correlation model of biomarker and primary 
endpoint can be written as:  
(
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and the unconditional joint distribution could be expressed as: 
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The new variable   , incorporated in the model, and its distribution accounts for the 
mean-level correlation between biomarker and primary endpoint. The uncertainty, due to 
a small sample size of historical data, about the relationship between the two endpoints 
should be reflected in the model in this way. The conventional one-level correlation 
model treats    as the true mean-level correlation    for simulation, which might be 
inappropariate. 
 
3.4.3 Test Statistic and its Distribution 
Consider the following hypotheses: 
      
     
     
     
    
      
     
         
     
        
     
    
We want to test if there is any treatment that shows significantly better efficacy than the 
control group. 
It is reasonable to assume that   
     
     
     
   when   
     
     
     
   
and    . For simplicity, assume   
  is known. 
Let the test statistic comparing the primary endpoint of the jth treatment group and the 
control group be:  
   √
 
  
  (  
  ̂ )
 
   
 ̂  (  
  ̂ )
 
   
 ̂    
(  
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)            for        . 
   is expected to approximately follow the standard normal distribution under    when 
the sample size is large.  
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The final test statistic of the study with the given interim selection rule is then: 
     , if    
   ̅̅ ̅̅ ̅
     (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)               . 
That is, conditional on the interim selection,  takes on the value of the effect from the 
“winner” treatment group as the final test statistic. 
In the following, we derive the asymptotic distribution of the final test statistic. For the 
very general case under   , the distribution of the final test statistic  could be written 
as: 
      ∑  (                    )
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             is approximately from a multi-normal distribution, 
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3.4.4 Type I Error Control 
It is shown that the interim treatment selection will skew the distribution of the final test 
statistic. Hence the type I error rate of the design might be inflated if no statistical 
adjustment is made. In this section, we find the adjusted critical rejection values of the 
final test statistic for preserving the type I error rate. 
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It is easy to show that, under   , the distribution of final test statistic is: 
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Let    be the upper      percent quantile of   , 
     
             
         
The type I error rate of the design is controlled at level α if the 1-sided rejection region is 
  {      }. The numerical values of    could be calculated using the R function 
wang_cv_K4 developed by us in Chapter 2. 
In addition, if we assume    
     
     
     
 , that is the variability of the estimated 
mean-level correlation for each treatment group is the same, the distribution of final test 
statistic  under    can be approximated by: 
       ∫ ∫ ∫                     
  
 
  
 
 
  
   
where             is p.d.f of ((
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 . 
The numerical values of    could be calculated using the R function convention_cv_K4 
in this case. 
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3.5 Performance Evaluation of Two-Stage Winner Design under Proposed 
Model  
In this section, we show performance evaluation of the two-stage winner design using our 
proposed two-level correlation model. As illustrated earlier, when the rank order of mean 
responses of the biomarker is assumed to be the same as that of the primary endpoint, the 
power of a two-stage winner design could be easily overestimated if the conventional 
one-level correlation model is used. It will be shown that the new assessment approach is 
more reasonable, and can help with determining when a two-stage winner design should 
be used. 
Assume   
    ,   
   ,   
    ,   
    – this  could always be achieved by scaling –
and assume   
      ,   
      ,   
      . We assume biomarker and primary 
endpoint are positively related, that is, large values of biomarker measurements 
correspond to large values of the primary endpoint. We consider the following cases 
when the means of biomarker and primary endpoint are correlated in linear and in non-
linear ways (Figure 3.2). 
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Figure 3.2 Mean Level Correlation Shapes 
 
3.5.1     and     are Linearly Related 
If the standardized mean of biomarker     and the standardized mean of primary 
endpoint     are linearly related, as shown in Figure 3.2, then the mean-level correlation 
   is the same for all treatment groups. Under our assumption here,             
 . Therefore,   
      ,   
      ,   
      , in this case.  
Consider the design with interim sample size       and maximum sample size 
     ; and       and      ; respectively. The two sample size will yield 80% 
and 90% power, respectively, of the corresponding classical design with no interim 
adaptation.  
Table 3.2 and Table 3.3 list the simulation results of the two-stage winner design under 
our setting for the above sample sizes for different values of ρ and   
 . All the simulation 
results are based on 10,000 simulation iterations. 
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Table 3.2 Power when     and     are Linearly Related (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  
0 87.8% 88.0% 88.0% 88.3% 88.8% 
0.1 83.8% 84.0% 84.0% 84.1% 85.3% 
0.2 79.0% 79.3% 79.4% 80.2% 80.4% 
 
Table 3.3 Power when     and     are Linearly Related (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  
0 94.2% 94.5% 94.6% 94.6% 94.9% 
0.1 92.0% 92.0% 92.2% 92.5% 92.8% 
0.2 88.9% 89.1% 89.2% 89.4% 89.8% 
 
 
We can see that, when   
  is fixed, the power of the design for different values of ρ is 
similar. For example, in Table 3.2, when   
     , the power of the design is around 
79%~80%. However, when ρ is fixed, the power of the design has a significant drop 
when   
  increases. For example, in Table 3.2, for      , the power of the design drops 
from 88% to 79.4% when   
  increases from 0 to 0.2. The results indicate that the 
individual level correlation ρ has only a little influence on the performance of the two-
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stage winner design, while   
 , which measures the uncertainty of the estimated mean-
level correlation has a significant influence on the design performance. Therefore, it is 
necessary to consider and incorporate   
  when evaluating a biomarker informed adaptive 
design. In the conventional one-level correlation model, since   
  is not considered, the 
power of the design can be easily overestimated. The simulation results also suggest that 
the two-stage winner design is not necessarily always better than the corresponding 
classical design. In our setting here, only when   
      does the two-stage winner 
design show its advantage in terms of power. 
 
3.5.2     and     are Not Linearly Related 
Case 1 and case 2 in Figure 3.2 show two possible shapes when the mean of biomarker 
    and mean of primary endpoint     are not linearly related. 
We assume   
         
         
       in case 1 and   
          
        
  
        in case 2. Simulation results of the two-stage winner design with interim 
sample size       and maximum sample size       for these two cases are listed in 
Table 3.4 and Table 3.5 respectively. The results agree with the previous findings when 
    and     are linearly related. The individual level correlation ρ does not show large 
influence on the power performance of the design; however,   
  shows significant 
influence. 
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Table 3.4 Power when     and     are Not Linearly Related – Case 1 (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  
0 90.3% 90.2% 90.5% 91.2% 91.8% 
0.1 80.2% 80.3% 81.6% 82.1% 82.9% 
 
Table 3.5 Power when     and     are Not Linearly Related – Case 2 (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  0 76.5% 76.9% 77.8% 78.6% 79.5% 
 
Different from what has been shown when     and     are linearly related, under the 
setting for case 1, the simulation results suggest that the two-stage winner design is a 
better option than the corresponding classical design only when   
     ; the simulation 
results also suggest that, under the setting for case 2, the two-stage winner design would 
never be better than the corresponding classical design. Therefore, the two-stage winner 
design is not necessarily better than the corresponding classical design. The performance 
of the two-stage winner design is affected by how     and     are related and the 
uncertainty about the mean-level correlation. 
Another interesting index for the performance of the two-stage winner design is “power 
with best treatment”, which is the probability that the final hypothesis will be rejected 
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when the best treatment is selected at interim. Table 3.6 – Table 3.9 list the “power with 
best treatment” under the above scenarios associated with Tables 3.2 – Table 3.5.  
 
Table 3.6 Power with Best Treatment when     and     are Linearly Related (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  
0 78% 78% 78% 78% 78% 
0.1 75% 75% 75% 76% 77% 
0.2 70% 70% 71% 71% 72% 
 
Table 3.7 Power with Best Treatment when     and     are Linearly Related (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  
0 85% 85% 85% 86% 86% 
0.1 83% 83% 83% 84% 84% 
0.2 81% 81% 81% 82% 82% 
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Table 3.8 Power with Best Treatment when     and     are Not Linearly Related – Case 1 (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  
0 90% 90% 90% 91% 91% 
0.1 80% 80% 81% 82% 82% 
 
Table 3.9 Power with Best Treatment when     and     are Not Linearly Related – Case 2 (           ) 
Power 
  
0 0.2 0.5 0.8 1 
2
r  0 60% 60% 60% 60% 61% 
 
It has been seen that, in general, the “power with best treatment” is lower than the power. 
However, the difference is affected by the shape of the mean-level relationship. When 
    and     are not linearly related, and have a relationship shape similar with the case 1 
in Figure 3.2, the difference between “power with best treatment” and the power is small, 
as can be seen by comparing Table 3.4 and Table 3.8. When     and     are not linearly 
related, and have a relationship shape similar to case 2 in Figure 3.2, the difference 
between the two powers is large. These facts indicate that the probability of choosing the 
best treatment at interim is affected by the shape of the mean-level relationship of the two 
endpoints used in design. 
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3.6 Parameter Estimation 
In this section, we propose a solution to the question “How to estimate the parameters 
incorporated in the two-level correlation model using historical data?” 
It is clear that the two-level correlation model incorporates the following parameters:   , 
  
  ,   ,   
  ,    
  and  ,          . 
Assume there are    pairs of historical data for treatment   on biomarker and primary 
endpoint,           . . Let    
  be sample variance of biomarker   
   
 in treatment 
group  ,         , and     
̅̅ ̅̅ ̅ be the observed sample mean of biomarker in treatment 
group  . Let    
  be sample variance of primary endpoint   
   
 in treatment group  , and 
    ̅̅ ̅̅ ̅ be the observed sample mean of primary endpoint in treatment group  .  
We suggest estimating the parameters in the following natural way: 
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 ̂            , which is the observed correlation coefficient of the pooled sample of 
  
   
 and   
   
,         ,            . 
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Detailed derivation of Equation (3.1) is provided in Appendix B. An approximation for 
the variance of ratio was used in derivation (Stuart and Ord, 1998). 
There are times when a common variance is preferred for    , i.e.,    
         
  
   
    
   will be assumed. For this case, we suggest:    ̂  ∑       ̂   ∑  . 
Table 3.10 lists the simulation results, and compares the true parameter values with their 
estimates. The 3 cases in Figure 3.2 were considered. We assume      , and the 
simulation results are based on 50 pairs of historical data for each treatment group. The 
numbers show that the proposed approach provides reasonable estimation for parameters. 
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Table 3.10 Estimation of the Parameters 
 
Linear Nonlinear 1 Nonlinear 2 
True Estimate True Estimate True Estimate 
  0.5 0.51 0.5 0.52 0.5 0.50 
2
Y  1 1.00 1 1.00 1 1.00 
0
Yu
 
1 1.01 1 1.00 1 1.00 
1
Yu
 1.1 1.11 1.1 1.11 1.1 1.11 
2
Yu
 1.5 1.50 1.5 1.50 1.5 1.51 
3
Yu
 1.3 1.31 1.3 1.31 1.3 1.31 
2
X  1 1.00 1 1.00 1 1.00 
0
Xu
 
1 1.00 1 1.01 1 1.01 
1
Xu
 1.1 1.11 1.2 1.22 1.05 1.07 
2
Xu
 
1.5 1.51 2.5 2.50 1.25 1.26 
3
Xu
 1.3 1.30 1.8 1.80 1.15 1.16 
0r  1 1.02 1 1.01 1 1.00 
1r  1 1.01 0.92 0.92 1.05 1.05 
2r  1 1.00 0.6 0.60 1.2 1.21 
3r  1 1.01 0.72 0.73 1.13 1.14 
2
r  0.014 0.015 0.01 0.0104 0.017 0.019 
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3.7 Discussion 
In this new age of personalized medicine, biomarker informed adaptive designs are very 
attractive. They have the potential to shorten the time of drug development and to bring 
the right drug to patient earlier, by incorporating correlated short-term endpoint at the 
interim stages. 
It is strongly suggested that statistical simulations should be performed before a drug trial 
to understand the operating characteristics of the trial design. As an important component 
of this process, a model need to be specified for simulation of the two endpoints 
incorporated in the study.  The conventional one-level correlation model used might be 
inappropriate when the relationship between the biomarker and the primary endpoint is 
not well known. This model only considers the individual-level correlation between the 
interim and final endpoint of the design, but ignores the uncertainty of the estimated 
mean-level correlation between the two endpoints. Hence, the simulation results of a 
biomarker informed adaptive design using the conventional one-level model can easily 
misestimate the power. 
We propose a new two-level correlation model for fitting the two endpoints in a 
biomarker informed adaptive design in this chapter. The new two-level correlation model 
incorporates correlations at both the individual and mean level. It is shown that in a 
biomarker informed adaptive design, the power is much more sensitive to the correlation 
between biomarker and primary endpoint at mean level than the correlation at the 
individual level. Simulations using the two-level correlation model for biomarker 
informed designs produce more sensible and reasonable results.  
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The proposed two-level correlation model is illustrated in the context of a two-stage 
winner design in this chapter. With the derived distribution of the test statistics and 
stopping boundary information, the type I error rate can be controlled. We considered 3 
cases where the mean-level correlations are in different shapes. It is shown that the shape, 
together with the uncertainty about the shape, should be counted when comparing the 
biomarker informed adaptive design with the corresponding classical design. An absolute 
advantage of the biomarker informed design is not guaranteed. In addition, it's also 
shown that the shape of the mean level correlation affects the probability of choosing the 
best treatment at interim of the design. 
Methods were proposed to estimate the parameters. The proposed estimators for the 
parameters appear to be unbiased by simulations. Hence, based on the prior historical 
data, we will be able to answer questions such as “which design will provide higher 
power, the biomarker informed adaptive design or the classical Dunnett design”, and, 
“what should the sample size be in order to get 80% power” by simulations. 
In general, when a good portion of the relationship between the biomarker and the 
primary endpoint is known, the biomarker informed design is recommended.  
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CHAPTER 4  
BIOMARKER INFORMED ADD-ARM DESIGN FOR UNIMODAL RESPONSE 
 
4.1 Introduction 
In drug development, identification of effective doses (or therapies) and inference on 
selected treatments are usually performed in two separate trials, i.e. separate phase II and 
phase III trials.  
For dose-finding, the traditional approach relies on analysis of variance (ANOVA) to 
compare the efficacy of each dose to control, using Dunnett’s adjustment (Dunnett, 1955) 
for multiplicity adjustment. The data analysis is pre-specified and no adaptation is used in 
either the design or the analysis. Adaptive approaches have also been proposed for 
designing and analyzing dose-response studies, with the purpose of optimizing the 
assessment of the dose-response relationship and narrowing down the set of candidate 
doses to select the estimated target dose. In general, these adaptive procedures can be 
categorized into two classes: “analysis-focused adaptive approaches” and “design-
focused adaptive approaches” (Bornkamp et al. 2007).  
The “analysis-focused adaptive approaches” relies on a fixed study design, that is, no 
design modifications are performed during the study. In this case, the focus is on 
selecting the most appropriate data analysis method. The choice of the “best” method is 
adaptive in the sense that it is driven by the data collected in the trial. The multiple 
comparison procedures-modeling approach (MCP-Mod) proposed by Bretz et al. (2005), 
Bayesian modeling-averaging approach (BMA), multiple trend test approach (MTT) and 
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nonparametric dose-response modeling approach (LOCFIT) are analysis-focused 
adaptive approaches.  
The “design-focused adaptive approaches” include methods that allow modifications of 
certain elements of the study design based on the data collected in the trial. For example, 
based on the review of interim safety or efficacy data, the trial’s sponsor can decide to 
drop one or more doses or reduce the number of patients assigned to these doses. This 
adaptation can be performed in a continuous manner, i.e., the design can be updated prior 
to the enrollment of each new patient. Alternatively, one can consider group-sequential 
adaptive strategies and perform design modifications based on responses from cohorts of 
patients. Examples of design-focused adaptive approaches include: Bayesian general 
adaptive dose allocation (GADA) and D-optimal response-adaptive approach (D-Opt). 
Recently, adaptive seamless designs have been explored. These designs combine dose 
selection and confirmation into one trial, so that the overall development time for a drug 
might be shortened and the number of patients needed for the trial might be reduced. A 
well-known example of the seamless design is Phase II/III drop-the-loser design (Bauer 
el al. 1999). Chang and Wang (2013) proposed a 3-stage add-arm design for unimodal 
dose-response, which is also an example of seamless design for dose selection and 
confirmation. This design utilizes the prior knowledge about the dose-response to 
optimize the procedure of dose-finding. If it is known that the dose-response curve is 
unimodal (e.g. anti-angiogenic agents or mixed agonist-antagonists), some poor candidate 
doses could be identified based on interim outcomes and hence patients need not be 
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exposed to those doses. It was shown that this design can save sample size by as much as 
20% compared with two-stage drop-the-loser design with unimodal response. 
One potential challenge of both the drop-the-loser design and the 3-stage add-arm design 
for unimodal response is that, the benefits of the designs might be limited if the endpoint 
at interim analysis takes very long to obverse. For example in the 3-stage add-arm design: 
the arm(s) added at the second stage are determined by the observed data from the first 
stage. An endpoint that takes long to observe at interim can be operationally challenging 
in this case. Besides, the long “white space” between the two stages might add a temporal 
effect. 
To circumvent some of these issues, we propose a “biomarker informed add-arm design 
for unimodal response” in this manuscript. The new design contributes to optimizing the 
procedure of dose-finding when a biomarker of the study primary endpoint exists and 
prior evidence indicates a unimodal dose-response relationship. In our proposed design, 
the interim decisions are based on the measurements of the biomarker, which is a short-
term endpoint that is correlated with the primary endpoint. Without loss of generality and 
for the purpose of this discussion, we assume the biomarker and the primary endpoint are 
positively related, that is, large values of biomarker measurement correspond to large 
values of the primary endpoint. Designs with up to 7 active treatment arms are 
considered. For the two endpoints (the biomarker and primary endpoint) incorporated in 
the design, we use the two-level correlation model developed in Wang et al. (2013) to fit 
them. We propose a statistical approach that controls the type I error rate of the proposed 
design, and carry out extensive simulation studies to study the power performance of the 
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design. The new design is compared against its corresponding biomarker informed two-
stage winner design (Shun et al. 2008) in a variety of settings, including different 
relationship between the two endpoints and different unimodal shapes of dose-response 
curve. Our proposed design is shown to outperform the corresponding biomarker 
informed two-stage winner design in power on an average. 
 
4.2 Biomarker Informed Add-Arm Design with 4 Active Treatment Arms 
4.2.1 The 3-Stage Design 
We make the assumption that the dose-response curve for the candidate drug is unimodal, 
and there exists a biomarker which is positively (or negatively) correlated with the 
response. In this section, we present the 3-stage biomarker informed add-arm design we 
proposed. 
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Figure 4.1 Biomarker Informed Add-Arm Design (4+1 Case) 
 
Assume there are 4 active treatment arms (dose levels 1, 2, 3, 4) and a control arm. The 
order of dose levels suggests an increasing potency. The biomarker informed add-arm 
design starts with randomizing patients into mid-level doses 2, 3, and the control group 
(denoted by “dose 0”). After    patients are treated with either dose 2 or dose 3, the 
observed measurements of biomarker for the two treatment groups are compared. If dose 
2 group has better response on biomarker than dose 3 group, patients are randomized to 
dose 1 group and the control group for the next stage. Likewise, if dose 3 group has better 
response on biomarker than dose 2 group, patients are randomized to dose 4 group and 
the control group at stage two. 
At the second interim look, the dose group added after evaluation at stage one will be 
compared with the “winner” dose group from stage one on biomarker. For example, if 
dose 2 is the “winner” from stage one, then dose 1 will be added into the study, hence at 
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the second interim analysis the biomarker results for dose 1 group will be compared to 
that for dose 2 group. The winner at this stage will be selected as the “best” dose 
candidate to carry to the end of the study with the control group. Additional    patients 
will be used for both of the “best” dose candidate and the control, and the final analysis 
will use patients from both stages on study primary endpoint. In this design, patients need 
not be exposed to every candidate dose. 
 
4.2.2 Mathematical Notations for the Design 
Let   be number of treatment groups (    active treatment groups, and 1 control 
group),   be the maximum sample size for each dose,        . Let {  
      
      } be measurements of the biomarker for  th patient in  th dose group; and 
{  
           } be measurements of the study primary endpoint.            . 
    represents the control group and           the active treatment groups. For 
simplicity, assume both the endpoints are normally distributed. 
We use the two-level correlation model proposed in Wang et al. (2013) for modeling the 
two endpoints, that is, assume 
(
  
   
  
  
   
  
   
)  ((
  
  
    
  )  (
  
  
))  
    (     
 )  
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where   
  is the variance of biomarker,   
  is the variance of study primary endpoint,   
   
is the standardized mean of biomarker for treatment group  .    is a random variable that 
describes the observed mean level correlation (or “mean level association”) between the 
biomarker and primary endpoint for treatment group   from historical data. Assume    is 
normally distributed, with mean    , which is the true mean level correlation between the 
biomarker and the primary endpoint; and variance   
 . The standardized mean of study 
primary endpoint for treatment group  ,   
  , can therefore be expressed as   
       
  . 
Assume {  
            } and {  
            } are correlated with a correlation ρ for 
the same   and  . 
Let    
   ̅̅ ̅̅ ̅
 
 
  
∑  
   
 be the mean of biomarker measurements for treatment group   at 
interim, and   
   ̅̅ ̅̅ ̅
 
 
 
∑  
   
 be the mean of primary endpoint measurements for treatment 
group   at final. The detail randomization and dose selection procedures of the design are 
as follows (Figure 4.2): 
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Figure 4.2 Detailed Biomarker Informed Add-Arm Design (4+1 Case) 
 
Stage 1: Assign       subjects in dose group 2, 0, and 3 using randomization ratio 
       . 
Stage 2: If the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       subjects in dose group 0 and 1 
using       randomization. Otherwise, if the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       
subjects in dose group 0 and 4 using       randomization. 
Stage 3: (a) If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
 and    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅    , select dose 2 as the best dose candidate 
among the 4 dose candidates; otherwise, select dose 1 as the best dose candidate. If 
   
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
 and    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅    , select dose 3 as the best dose candidate among the 4 
dose candidates; otherwise, select dose 4 as the best dose candidate. (b) Assign     
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subjects in the selected best candidate dose group and the control group using     
randomization. 
In total, there will be         subjects. The final analysis will use measurements of 
study primary endpoint from       subjects in the selected best dose candidate group 
and the control group. 
Notice that the randomization ratio being used at the first stage of the design is         
instead of      . This is because that         can keep the treatment blinding and 
balance the confounding factors at the second stage. If       was used, then    subjects 
would be randomized to the control group at the first stage, hence all the subjects have to 
be assigned to the active treatment group without randomizing at the second stage, thus 
unblinding the treatment and potentially imbalance of any baseline confounding factors. 
Also notice that the criteria being used at the second stage for selecting the best candidate 
dose is comparing    
   ̅̅ ̅̅ ̅
 with    
   ̅̅ ̅̅ ̅
   , and comparing    
   ̅̅ ̅̅ ̅
 with    
   ̅̅ ̅̅ ̅
   . In next 
section we discuss how to determine the constant   .  
 
4.2.3 Find      
Define the term “selection probability” as the probability of selecting a dose level as the 
preferred treatment for the next stage of the adaptive trial. 
If     , the proposed design becomes a biomarker informed 3-stage winner design, in 
which the active treatment group with the maximum observed response on biomarker at 
the current stage is picked as the winner. The problem in this approach is the selection 
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probability will be skewed for a flat response curve. More specifically in our case, the 
selection probability of dose 1, 2, 3, and 4 will be 1/6, 2/6, 2/6 and 1/6, respectively when 
in fact all doses have the same effect. 
We expect equal selection probability for each dose group while all doses have the same 
effect. Thus, we force the probability of selecting each dose equal (or at least 
approximately equal) under   
     
     
     
     
  , i.e., the following equations 
need to hold (or approximately hold): 
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, the conditional probability can be written as: 
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The integration could be solved by the numerical software. It shows that 
  
√
   
 
  
 is a 
constant, 
  
√
   
 
  
     . 
Thus,    is a function of    and   
 ,        √
   
 
  
. 
  
  is suggested to be substituted by the sample variance   
 ̂ for calculating   , as   
  is 
unknown in practice. The obtained    is suggested to be further validated via simulations 
to ensure an (approximately) equal selection probability of each dose group for a flat 
response curve.  
 
4.2.4 Type I Error Control 
The type I error rate of a trial that uses biomarker informed add-arm design can be 
preserved by adjusting the critical rejection value of its final test statistic. In this section, 
we demonstrate how to adjust the critical rejection value for type I error control and 
develop R function for this purpose. 
Let us consider the following hypotheses: 
      
     
     
     
     
    
      
     
        
     
        
     
        
     
     
It is reasonable to assume that   
     
     
     
     
   when   
     
     
   
  
     
   and    . 
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Let    be the test statistic comparing the primary endpoint of the  th treatment group and 
the control group. The final test statistic for the biomarker informed add-arm design with 
4 active treatments can then be expressed as the following: 
  
{
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That is, conditional on the interim selection,  takes the value of the effect of the 
selected best dose candidate group as the final test statistic. 
For a general case under   , the distribution of the final test statistic  can be derived as 
the following: 
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Under   , the distribution of the final test statistic can be simplified as: 
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Let    be the upper      percent quantile of   ,  
     
             
         
The type I error rate of the design can be controlled at level α if the 1-sided rejection 
region is   {      }. 
It can be seen that the critical rejection value    is a function of interim information time 
  
 
 and ρ. 
To calculate the critical rejection values    for the biomarker informed add-arm design 
with 4 active treatment arms, we develop an R function addarm_cv_K5 (Appendix A). 
This function can be used to calculate the critical rejection values for any values of   ,  , 
ρ and α. Table 4.1 lists the values of        for the biomarker informed add-arm design 
with different values of interim information time 
  
 
 and ρ. As expected, the critical 
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rejection value        increases as ρ increases. Further, it can be seen that, when the 
interim information time increases, the critical rejection value        increases. 
 
Table 4.1 Critical Rejection Value        
ρ 0 0.2 0.5 0.8 1 
   ⁄      
       1.96 2.02 2.101 2.172 2.214 
   ⁄      
       1.96 2.037 2.137 2.221 2.267 
   ⁄      
       1.96 2.056 2.176 2.27 2.317 
 
4.2.5 Power 
The biomarker informed add-arm design we proposed uses the biomarker indication of 
the primary endpoint for interim decision(s), and the assumption of a unimodal dose-
response curve to avoid testing every candidate dose level. Some poor performing doses 
can be identified, and hence patients need not be exposed to these doses.  
In this section, we compare our proposed design against the biomarker informed two-
stage winner design. The biomarker informed two-stage winner design was proposed and 
studied in Shun et al. (2008). It starts with several active treatment arms and a control 
arm. At interim, the inferior arms will be terminated based upon results for biomarker, 
and only the most promising treatment (“winner”) will be retained and carried to the end 
of the study with the control arm. The final comparison between the winner arm and the 
control arm will be performed on data from both stages and on study primary endpoint. In 
biomarker informed two-stage winner design, patients need to be exposed to every 
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candidate dose, though only a small number of patients will be exposed to the poor 
performing doses. We consider a variety of settings, including different kinds of 
correlations between the biomarker and the primary endpoint and different shapes of the 
unimodal dose-response curve, and compare the power performance of  the biomarker 
informed add-arm design with the biomarker informed two-stage winner design. Our 
proposed design is shown to outperform the biomarker informed two-stage winner design 
on average. 
 
4.2.5.1 Power-Performance Simulation: Design 
As presented in Wang et al. (2013), the power of a biomarker informed adaptive clinical 
trial design depends on the shape of mean-level correlation between the biomarker and 
the primary endpoint, the uncertainty about the shape, and the individual-level correlation 
ρ between the two endpoints. It was shown that, a biomarker informed two-stage winner 
design is a better choice than a corresponding classical design when the shape of the 
mean-level correlation is as that is shown in Figure 4.3, and the uncertainty   
     . 
Hence for the power-performance comparison between our proposed design and the 
biomarker informed two-stage winner design, we consider the two shapes of mean-level 
correlation in Figure 4.3, different values of   
  (  
     ) and different values of ρ. 
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Figure 4.3 Mean Level Correlation Shapes 
 
The power performance of a biomarker informed two-stage winner design is not affected 
by the dose order. However, in the biomarker informed add-arm design we proposed, a 
different dose order implies a different dose-response relationship and a different testing 
order, hence the power of the design might be different. In the comparison of the power 
performance between our proposed design and the biomarker informed two-stage winner 
design, we therefore also consider different dose orders, that is, different shapes of the 
unimodal dose-response curve. The 3 different unimodal dose-response curves we 
considered are shown in Figure 4.4. 
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Figure 4.4 Dose Response Curves 
 
In our simulation, we assume   
       
      
       
    – this could always be 
achieved by scaling. Assume the standardized mean response of primary endpoint for the 
4 active treatment groups are 1.1, 1.3, 1.4 and 1.5, respectively. If     and     are 
linearly related, then the standardized mean response of biomarker for the 4 active 
treatment groups are 1.1, 1.3, 1.4 and 1.5, respectively. If     and     are nonlinearly 
related as in shown Figure 4.3, assume the standardized mean response of biomarker for 
the 4 active treatment groups are 1.2, 1.7, 2 and 2.1, respectively. 
Consider the biomarker informed designs with total sample size 420. This sample size 
will yield 85% power of a corresponding classical design with no interim adaptation 
using Dunnett’s test for multiplicity adjustment. Assume the interim adaptations based on 
biomarker response take place when the information time is 0.5 (i.e. 
  
 
    ). The 
simulated power results for the biomarker informed add-arm design and the biomarker 
informed two-stage winner design under different scenarios are presented in next section. 
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4.2.5.2  Power-Performance Simulation: Results 
Table 4.2-Table 4.5 list the simulated power results for the two designs.  
 
Table 4.2 Power: Biomarker Informed Two-Stage Winner Design (Linear) 
Power ρ 
  
  0 0.2 0.5 0.8 1 
0 91.4% 92.2% 92.3% 93.3% 93.8% 
0.1 88.7% 88.7% 88.7% 90.2% 90.6% 
0.2 84.5% 84.7% 85.8% 86.5% 86.6% 
 
 
Table 4.3 Power: Biomarker Informed Two-Stage Winner Design (Nonlinear) 
Power ρ 
  
  0 0.2 0.5 0.8 1 
0 93.6% 93.7% 93.9% 94.2% 94.9% 
0.1 88.6% 88.6% 88.8% 89.1% 89.8% 
0.2 82.3% 82.6% 82.6% 82.9% 83.9% 
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Table 4.4 Power: Biomarker Informed Add-Arm Design (Linear) 
Power     Shape 1 
                Shape2 
                Shape3 
 
  
  
  0 0.2 0.5 0.8 1 
 
0 
88.6% 
92.6% 
94.8% 
89.6% 
93.4% 
95.1% 
90.1% 
93.9% 
95.5% 
90.8% 
94.0% 
95.8% 
91.2% 
95.2% 
96.2% 
 
0.1 
85.7% 
89.9% 
93.0% 
86.1% 
89.9% 
93.1% 
87.3% 
91.0% 
93.4% 
88.2% 
92.2% 
93.6% 
88.5% 
92.4% 
94.0% 
 
0.2 
83.2% 
87.5% 
90.4% 
83.4% 
87.2% 
90.4% 
83.6% 
87.9% 
91.1% 
85.1% 
89.2% 
91.2% 
85.8% 
89.4% 
92.1% 
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Table 4.5 Power: Biomarker Informed Add-Arm Design (Nonlinear) 
Power      Shape 1 
                Shape2 
                Shape3 
 
  
  
  0 0.2 0.5 0.8 1 
 
0 
96.3% 
95% 
96.5% 
96.6% 
95.7% 
96.6% 
96.6% 
95.9% 
96.6% 
96.9% 
96% 
97.2% 
97.2% 
96.1% 
97.3% 
 
0.1 
93.1% 
90.8% 
92.5% 
93.1% 
90.9% 
92.9% 
93.1% 
91.2% 
93.1% 
93.2% 
92% 
93.3% 
93.6% 
92.4% 
94% 
 
0.2 
88.4% 
85.5% 
87.6% 
88.5% 
86.3% 
87.7% 
88.3% 
86.4% 
87.9% 
88.5% 
86.8% 
88.2% 
88.9% 
86.8% 
89.0% 
 
Table 4.2 and Table 4.3 report the power of the biomarker informed two-stage winner 
design (4 active treatment arms and 1 control) for different values of ρ and   
  when     
and     are linearly and nonlinearly related respectively. The simulation results are 
consistent with what was found in Wang et al. (2013): when   
  is fixed, the power mild 
increases as ρ increases; however, the power drops significantly as   
  increases for a 
fixed ρ. The biomarker informed two-stage winner design is in general better than a 
classical design when   
      if     and     are linearly related; however, when     
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and     are nonlinearly related as shown in Figure 4.3, the biomarker informed two-stage 
winner design will be a better choice only when   
     .  
Table 4.4 and Table 4.5 present the power of the corresponding biomarker informed add-
arm design with different dose-response curves when     and     are linearly and 
nonlinearly related respectively. As seen, ρ only plays little role on power of the 
biomarker informed add-arm design, while   
  plays a significant role.  
Further, we can see that the shape of dose-response curve and the shape of mean level 
correlation affect the power performance of the biomarker informed add-arm design. 
When the mean level correlation between biomarker and primary endpoint is linear, i.e., 
    and     are linearly related, the design with dose-response curve in shape 3 of Figure 
4.4 has the highest power, while the design with dose-response curve in shape 1 has the 
worst power. Comparing Table 4.4 with Table 4.2, the power of a biomarker informed 
add-arm design with dose-response shape 3 is generally 2%~5% higher than a 
corresponding biomarker informed two-stage winner design; the power of the design with 
dose-response shape 2 is 1%~2% higher than the corresponding biomarker informed two-
stage winner design; while the power of the design with dose-response shape 1 is 1%~3% 
lower than the corresponding biomarker informed two-stage winner design. When the 
mean level correlation between the biomarker and primary endpoint is nonlinear as 
shown in Figure 4.3, for all the 3 dose-response curves we considered, the biomarker 
informed add-arm design has better performance on power. According to our simulation, 
the biomarker informed add-arm design is 2%~5% higher on power than a corresponding 
biomarker informed two-stage winner design. 
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On average, the biomarker informed add-arm design we proposed is better than the 
corresponding biomarker informed two-stage winner design in terms of power. 
 
4.3 Biomarker Informed Add-Arm Design with  (   ) Active Treatments 
In this section, we describe how to carry out the biomarker informed add-arm design for a 
clinical trial with more than 4 active treatments. Designs with up to 7 active treatments 
are proposed. 
 
4.3.1 Biomarker Informed Add-Arm Design with 5 Active Treatments 
 
 
Figure 4.5 Biomarker Informed Add-Arm Design for Unimodal Response (5+1 Case) 
 
Figure 4.5 shows the dose selection procedures for the biomarker informed add-arm 
design with 5 active treatment groups. 
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Stage 1: Assign       subjects in dose group 2, 0 and 4 using randomization ratio 
       . 
Stage 2: If the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       subjects in dose group 1, 0 and 3 
using         randomization. Otherwise, if the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       
subjects in dose group 3, 0 and 5 using         randomization. 
Stage 3: (a) If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
 and   (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)     
   ̅̅ ̅̅ ̅
   , select dose 1 group as the 
best candidate dose group; otherwise, select dose 2 or dose 3 group as the best candidate 
dose group depending on which has a larger response. If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
 and 
   (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)     
   ̅̅ ̅̅ ̅
   , select dose 5 group as the best candidate dose group; 
otherwise, select dose 4 or dose 3 group as the best candidate depending on which has a 
larger response. (b) Assign     subjects in dose group 0 and the selected best candidate 
dose group using     randomization. 
In total, there will be         subjects. The final analysis will use measurements of 
study primary endpoint from       subjects in the selected best candidate dose group 
and the control group. 
The default selection probabilities when      for the 5 doses in this design are: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
, respectively. To ensure every dose candidate has an equal selection 
probability when the response curve is flat (i.e., under   
     
     
     
     
   
  
  ), the following equation has to be hold: 
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 (    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
    (   
   ̅̅ ̅̅ ̅    
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   ̅̅ ̅̅ ̅        
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√
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   ̅̅ ̅̅ ̅̅
√
   
 
  
 , the conditional probability can be 
written as: 
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)  
(
  
 
(
 
 
 
)  
(
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
)
 
 
)
  
 
 under   
 .             is p.d.f. of           
 . 
The integration could be carried out by the numerical software. It shows that, 
  
√
   
 
  
 
    . Thus,    is a function of    and   
 ,        √
   
 
  
.  
  
  is suggested to be substituted by the sample variance    
 ̂ for calculating   . The 
obtained    is further suggested to be validated via simulations to ensure an 
(approximately) equal selection probability of each dose group for a flat response curve.  
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4.3.2 Biomarker Informed Add-Arm Design with 6 Active Treatments 
The dose selection procedures for the biomarker informed add-arm design with 6 active 
treatment groups are shown in Figure 4.6. 
 
 
Figure 4.6 Biomarker Informed Add-Arm Design for Unimodal Response (6+1 Case) 
 
Stage 1: Assign       subjects in dose group 3, 0 and 4 using randomization ratio 
       . 
Stage 2: If the observations     
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       subjects in dose group 1, 0 and 2 
using         randomization. Otherwise, if the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       
subjects in dose group 5, 0 and 6 using         randomization. 
Stage 3: (a) If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
 and    
   ̅̅ ̅̅ ̅
    (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)    , select dose 3 group as the 
best candidate dose group; otherwise, select dose 1 or dose 2 group as the best candidate 
dose group depending on which has a larger response. If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
  and    
   ̅̅ ̅̅ ̅
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   (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)    , select dose 4 group as the best candidate dose group; otherwise, 
select dose 5 or dose 6 group as the best candidate depending on which has a larger 
response. (b) Assign     subjects in dose group 0 and the selected best candidate dose 
group using     randomization. 
In total, there will be         subjects. The final analysis will use measurements of 
study primary endpoint from       subjects in the selected best candidate dose group 
and the control group. 
The default selection probabilities when      in this design are: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  , for 
the 6 doses, respectively. To make every dose candidate has an equal selection 
probability for a flat response curve (i.e., under the hypothesis   
     
     
     
   
  
     
     
  ), the following equation need to be hold: 
 (    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
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, the conditional probability can be 
written as: 
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where (
  
  
  
)  
(
  
 
(
 
 
 
)  
(
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
)
 
 
)
  
 
 under   
 .             is p.d.f. of           
 . 
By numerical software, 
  
√
   
 
  
      . Thus,    is a function of    and   
 ,    
     √
   
 
  
. 
  
  is suggested to be substituted by the sample variance    
 ̂ for calculating   . The 
obtained    is further suggested to be validated via simulations to ensure an 
(approximately) equal selection probability of each dose group for a flat response curve. 
 
4.3.3 Biomarker Informed Add-Arm Design with 7 Active Treatments 
The dose selection procedures for the biomarker informed add-arm design with 7 active 
treatment groups are shown in Figure 4.7. 
 
Figure 4.7 Biomarker Informed Add-Arm Design for Unimodal Response (7+1 Case) 
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Stage 1: Assign       subjects in dose group 3, 0 and 5 using randomization ratio 
       . 
Stage 2: If the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       subjects in dose group 1, 2, 4 and 0 
using           randomization. Otherwise, if the observations    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
, assign       
subjects in dose group 4, 6, 7 and 0 using           randomization. 
Stage 3: (a) If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
 and   (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)     (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)    , select dose 1 or 
dose 2 as the best candidate dose depending on which has a larger response; otherwise, 
select dose 3 or dose 4 as the best candidate dose depending on which has a larger 
response. If    
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
  and   (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)     (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)    , select dose 7 or 
dose 6 group as the best candidate dose group; otherwise, select dose 5 or dose 4 group as 
the best candidate depending on which has a larger response. (b) Assign     subjects in 
dose group 0 and the selected best candidate dose group using     randomization. 
In total, there will be         subjects required. The final analysis will compare 
measurements of study primary endpoint from       subjects in the selected best 
candidate dose group and the control group. 
The default selection probabilities when      for the 7 doses in this design are: 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
, respectively. To ensure every dose candidate has an equal 
selection probability for a flat response curve (i.e., under the hypothesis   
     
     
   
  
     
     
     
     
  ), the following equation need to be hold: 
 (   
   ̅̅ ̅̅ ̅
    
   ̅̅ ̅̅ ̅
    (   
   ̅̅ ̅̅ ̅    
   ̅̅ ̅̅ ̅)     (   
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   ̅̅ ̅̅ ̅)        
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Let    
   
   ̅̅ ̅̅ ̅̅
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 .                is p.d.f. of 
             
 . 
By numerical software, 
  
√
   
 
  
      . Thus,    is a function of    and   
 ,    
     √
   
 
  
. 
  
  is suggested to be substituted by the sample variance    
 ̂ for calculating   . The 
obtained    is further suggested to be validated via simulations to ensure an 
(approximately) equal selection probability of each dose group for a flat response curve. 
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In addition to comparing the observed means of biomarker at the interim stages for dose 
selection, comparing the observed values of t-statistic might be another option for interim 
decisions of a biomarker informed add-arm design. In a biomarker informed add-arm 
design that uses the observed t-statistic for interim decisions,    would be a constant that 
does not vary with    and   
 . 
 
4.4 Discussion 
In this chapter, we have proposed a new biomarker informed adaptive design called 
“biomarker informed add-arm design for unimodal response”. Designs starting with   
active treatment arms up to 7 active treatment arms were considered.  
This design combines the initial dose selection based on a biomarker and confirmation 
based on the primary endpoint into the same trial. It utilizes the existing knowledge about 
the shape of dose-response of the biomarker and determines the test order for doses to 
select the most efficacious dose for the next stage. It is different from the biomarker 
informed two-stage winner design where all treatments need to be explored while the 
biomarker add-arm design can identify some inferior treatments and hence no patients 
need to be exposed to those doses. Consequently, the proposed design may further reduce 
the expected sample size while gaining information about the effective dose more 
quickly. 
We discussed the approach for ensuring each dose has equal selection probability under 
flat response curve and proposed a statistical approach for controlling type I error of the 
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design. R function for calculating the adjusted critical rejection value for final test 
statistic of the design was developed. 
We carried out extensive simulation studies to study this design and to evaluate its 
performance against the corresponding biomarker informed two-stage winner design. It 
has been shown that the power of our proposed design is mainly affected by the shape of 
dose-response curve and the shape of mean-level correlation and its uncertainty. The 
power of the design is in general better, when the mode of the dose-response curve is in 
the middle, and the shape of mean-level correlation is nonlinear as shown in Figure 4.3. 
On average, the proposed design is better than its corresponding biomarker informed 
two-stage winner design. However, the benefits are different for different shapes of dose-
response, and the mean-level relationship.  
Our proposed design has the potential to efficiently use the existing information and 
resources and to select the most effective dose faster, but it suffers with the same 
limitation as any other biomarker informed adaptive designs, as it requires certain 
certainty about the surrogacy of the biomarker in order to ensure the advantage of the 
design. Though we have incorporated the parameters of uncertainty by using the two-
level correlation model proposed by Wang, et al. (2013) for design evaluation, careful 
consideration is strongly suggested before employing the proposed design. 
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CHAPTER 5  
A CASE STUDY OF USING BIOMARKER AT INTERIM 
 
5.1 Introduction 
Biomarker informed adaptive clinical trial designs, which make interim decisions based 
upon inference on biomarkers, have generated a great deal of attention in recent years. 
Using biomarkers for interim decisions can help forestall certain operational challenges, 
and have the potential to shorten the duration of the trial for drug development and 
prevent unnecessary waste of resources. But how much would we pay for this? 
In this chapter, we perform simulation studies for non-small cell lung cancer trials where 
change in tumor size is used as a biomarker of survival. The concordance rate of 
decisions made based upon survival times and changes in tumor size is investigated, and 
the factors that affect the concordance of decisions are explored. This study will help us 
better understand the profit and loss of using a biomarker for interim decisions. 
Different from previous chapters where we specify distributions for both endpoints in the 
study, a regression model linking the biomarker and primary endpoint will be specified to 
describe the relationship of the two endpoints. 
 
5.2 Survival Model in Non-Small-Cell Lung Cancer 
Change in tumor size can be used as a biomarker for survival in non-small-cell lung 
cancer.   
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Wang et al. (2009) developed a parametric model for survival times in non-small-cell 
lung cancer patients, utilizing data from four non-small-cell lung cancer registration 
trials. The parametric survival model they proposed includes baseline tumor size 
(centered at 8.5 cm), ECOG status (0/1/2/3 as a categorical variable) and percentage 
tumor reduction from baseline at week 8 (      ) as predictors of time to death ( ).  
The regression model is written as follows: 
                                                   
where   is the time to death (day),    is the intercept,   ,   ,    are the slopes for 
ECOG, centered baseline, and       , respectively, and     is the residual variability 
following a normal distribution with a mean of 0 and variance of    
 .  
A set of parameter estimates has been provided for the second-line treatments of non-
small-cell lung cancer: 
  ̂       
  ̂        
  ̂         
  ̂       
Thus,  
                                                          (5.1) 
This model has been shown to have good predictive ability by Wang et al. (2009). 
In the following, we utilize this model and carry out simulation studies to investigate the 
concordance between decisions made based upon        and based on survival   for a 
non-small-cell lung cancer trial using classical design.  
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5.3 Data Generation Based On Survival Model for Non-Small-Cell Lung 
Cancer 
As presented in Chapter 3, the individual-level correlation, the estimated mean-level 
correlation, and the uncertainty about the estimated mean-level correlation are three 
factors that determine the relationship of a biomarker and a primary endpoint.   
When the model (5.1) is specified, the estimated mean-level correlation is fixed. For 
simplicity, we consider the most ideal scenario and further assume that there is no 
uncertainty about this estimated mean-level correlation. Therefore, the individual-level 
correlation ρ is the only index in our case for describing the relationship between the two 
endpoints.   
A natural question is how to generate data for        and        so that they satisfy 
(5.1) and correlate with the correlation coefficient ρ. We address this question in this 
section. 
Assume               
  ,                   
  ,            
   and assume the 
mean ECOG score of patients is 0.5 and the baseline tumor size follows a normal 
distribution with mean 8.5 and variance 30, to make        and        correlate with a 
correlation coefficient ρ while preserving the above relationship (5.1), the following 
equations need to be satisfied (see proof in Appendix C): 
                                                                                                           (5.2) 
      
  
   
                                                                                                           (5.3) 
   
          
                                                                                                  (5.4) 
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By convention, we make assumptions for the primary study endpoint        (i.e.   ,   
 ). 
Data for        and        that satisfy (5.1) and correlate with a correlation coefficient 
ρ could be generated by the following procedure: 
(1) calculate     ,     
 , and    
  using (5.2)-(5.4) 
(2) simulate        from            
    and     from        
   
(3) calculate        using (5.1) 
For example, if we assume             (i.e. the mean survival time is around 6 
months),   
   , and ρ 0.5, using the above procedure if we generate 500 pairs of data; 
the sample correlation coefficient is 0.505. 
It is not recommended to simulate data for survival (       ) and     first, and calculate 
       from (5.1). If data were generated in this way, the sample correlation coefficient 
for the above example would be 0.75. The correlation between        and        
would not be preserved.  
Follow-up times could also be generated from another log-normal distribution to control 
the censoring rate for survival. 
 
5.4 Inference Based Upon Change in Tumor Size vs. Inference Based On 
Survival 
In this section, we investigate the concordance between decisions made by the tumor size 
changes at week 8 (      ) and by survival times (       ) in a non-small-cell lung 
cancer trial. The factors that affect the concordance of decisions are also explored. 
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For a more accurate result, we assume the trial uses a classical design. That is, the same 
number of patients will be used for inference based on tumor size change and on survival. 
The “interim” here refers to the short time needed for the measurements of tumor size 
change at week 8.  
Assume there are two arms, a treatment arm and a control arm. The patient populations in 
the two arms are assumed to share the same baseline characteristics, such as the baseline 
tumor size and the ECOG score. Assume the expected mean survival time for patients in 
the treatment arm is around 9 months (i.e.,             ), and the expected mean 
survival time for patients in the control arm is around 6 months (i.e.,             ). 
Assume   
   , then 191 patients are required in each arm to achieve 80% power of the 
design with 2-sided type I error rate controlled at 0.05.  
We generate patients’ records for week 8 tumor size change        and survival   using 
the procedure stated in the previous section. Follow-up times are also generated from log-
normal distributions to control the censoring rate. Four censoring rates we studied are 
0%, 5%, 10%, and 20%. We use t-test for comparing week 8 tumor size changes        
between the treatment arm and the control arm. For comparison of the survival times 
between the two arms, we consider two survival analysis methods: the log-rank test, 
which we use most of the time; and the survival analysis with lognormal distribution, 
when the survival distribution is specified correctly. 
We compare the decisions made based upon t-test for       , log-rank test for  , and 
survival analysis with lognormal distribution for  , and calculate the concordance rates of 
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decisions. The simulated results under different scenarios are listed in Table 5.1—Table 
5.3. 
 
Table 5.1 Concordance Rate: Design Specifications Assumed Correctly 
Concordance                 
      Rate                           
                                     
N=191,   
   ,                           
t vs. LR t vs. LN LR vs. LN 
Censoring Rate 
0% 
0.82 0.89 0.87 
0.74 0.83 0.86 
0.72 0.79 0.86 
5% 
0.80 0.88 0.88 
0.74 0.82 0.88 
0.71 0.80 0.88 
10% 
0.80 0.88 0.88 
0.74 0.81 0.89 
0.72 0.79 0.89 
20% 
0.80 0.89 0.89 
0.75 0.82 0.90 
0.71 0.79 0.89 
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Table 5.2 Concordance Rate:   
  Assumed Incorrectly 
Concordance                 
         Rate                         
                                      
N=191,   
   ,                           
t vs. LR t vs. LN LR vs. LN 
Censoring Rate 
0% 
0.76 0.84 0.84 
0.65 0.71 0.84 
0.46 0.53 0.86 
5% 
0.76 0.84 0.86 
0.62 0.68 0.86 
0.46 0.52 0.86 
10% 
0.77 0.83 0.86 
0.64 0.70 0.88 
0.46 0.53 0.87 
20% 
0.76 0.82 0.88 
0.63 0.70 0.88 
0.45 0.51 0.89 
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Table 5.3 Concordance Rate:     Assumed Incorrectly 
Concordance                 
       Rate                           
                                      
N=191,   
   ,                           
t vs. LR t vs. LN LR vs. LN 
Censoring Rate 
0% 
0.76 0.84 0.85 
0.64 0.72 0.84 
0.46 0.53 0.85 
5% 
0.78 0.85 0.87 
0.64 0.71 0.87 
0.45 0.52 0.87 
10% 
0.77 0.82 0.88 
0.63 0.70 0.89 
0.44 0.51 0.88 
20% 
0.76 0.82 0.89 
0.62 0.69 0.89 
0.43 0.49 0.90 
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Table 5.1 lists the simulated concordance rates for different values of ρ and censoring 
rate when the design specifications, including   
 ,    , and    , are assumed correctly. 
Table 5.2 lists the simulated concordance rates when   
  is assumed incorrectly: the true 
value for   
  is 4, but we mistakenly assume   
   . Table 5.3 lists the simulated 
concordance rates when the treatment effect is not assumed correctly: we assume a 3 
months difference in survival between the two different treatments, when in fact there is 
only 2 months’ difference in survival. 
We can see that, in general, censoring does not affect the concordance of decisions much 
if the censoring rate is controlled within 20%. By our simulations, the difference in 
concordance rates is within 3% for different values of the censoring rate. 
In all the scenarios we considered, the concordance between decisions by the two 
different survival analysis techniques are around 85%~90%. Thus, a 10%~15% 
difference in inference decisions will arise if we perform survival analysis using a non-
parametric method instead of specifying a correct survival distribution. 
In general, the concordance between decisions made based on        and decisions 
made based on   using survival analysis with a correct survival distribution is higher than 
the concordance between decisions by        and by   using log-rank test. 
Under our simulation settings, if all the design specifications (  
 ,    ,    ) are specified 
correctly, for a trial designed with 80% power, concordance of decisions by t-test for 
       and by log-rank test for   is also around 80% if the correlation between        
and   equals 0.9, i.e.,      . When the correlation coefficient ρ between the two 
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endpoints drops to 0.5, the concordance between decisions by        and that by   drop 
around 10%.  
If any of the design specifications is specified incorrectly, the concordance between 
decisions made based on        and based on   will decrease. Moreover in this case, 
when ρ drops from 0.9 to 0.5, the concordance rates of decisions drop around 30%. This 
indicates that sample size plays a role for the concordance between inference decisions 
based on interim biomarker and based on study primary endpoint when the mean-level 
relationship between the two endpoints is fixed.  
If we were able to assume all the design specifications correctly, that is if we have a 
sufficient sample size, even if   is small, the concordance rates are not terribly inaccurate 
in our case. For example in Table 5.1, when      , the concordance between decisions 
based on        and based on   using log-rank test is 72%. However, if any of the 
design specifications is assumed incorrectly, the concordance rates will be very poor 
when   is small. 
 
5.5 Discussion 
In this chapter, we studied the concordance between decisions made based on interim 
biomarker and based on study primary endpoint to better understand the profit and loss of 
using a biomarker for interim decisions. 
In the context of a classical non-small-cell lung cancer trial where a regression model 
linking the interim biomarker (change in tumor size) and primary endpoint (survival) has 
been developed, we proposed a procedure for generating data for the two endpoints and 
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carried out extensive simulation studies. The inference decisions made based on tumor 
size changes and based on survival times using two different survival analysis techniques 
were compared under different scenarios, and the concordance rates were calculated.  
It has been shown that censoring of survival times does not affect the concordance of 
decisions much if the censoring rate is controlled within 20%. However, performing 
survival analysis using different methods will produce a mild difference in the inference 
decisions. Around 10%~15% difference in decisions will arise if we perform survival 
analysis using non-parametric method instead of specifying a correct survival 
distribution.  
Sample size also plays a role in the concordance between inference decisions based on 
tumor size change and based on survival. When mean-level relationship between the two 
endpoints is fixed, if all the design specifications were assumed correctly (that is, if we 
have a sufficient sample size), the concordance of decisions would not terribly inaccurate 
even if the two endpoints correlated poorly. However, if any of the design specifications 
was specified incorrectly (meaning, if we underestimate the sample size required), the 
inference decisions based on a poor biomarker would be very different from that based on 
the primary endpoint. These findings agree with what we found in previous chapters. 
Simulations in this chapter are based on the assumption that there is no uncertainty about 
the regression model linking the interim biomarker (change in tumor size) and primary 
endpoint (survival). Concordance of inference decisions might be worse if we are unsure 
about this relationship. Therefore, serious consideration is strongly suggested before 
using a biomarker for interim decisions. 
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CHAPTER 6  
SUMMARY AND  
USING A BIOMARKER INFORMED ADAPTIVE DESIGN  
IN AN A&WC STUDY 
 
In this dissertation, we develop novel statistical methods for biomarker informed adaptive 
clinical trial designs.  
In Chapter 2, we propose a novel statistical approach for type I error control of the 
biomarker informed two-stage winner design. Our proposed method can work for the 
design with any number of treatment arms, which overcomes the limitation of the normal 
approximation method proposed by Shun et al. (2008). In Chapter 3, we develop a new 
two-level correlation approach to model the two endpoints in a biomarker informed 
adaptive design. A new variable that describes the mean level correlation is incorporated 
in the model. Compared with the conventional model which only considers the individual 
level correlation, the new model could reflect the uncertainty of the historical knowledge 
more accurately. In Chapter 4, we propose a new biomarker informed adaptive design 
called “biomarker informed add-arm design for unimodal response”. This design 
combines the initial dose selection based on a biomarker and confirmation based on the 
primary endpoint into the same trial. It utilizes the existing knowledge about the shape of 
dose-response curve and determines the test order for doses to select the most efficacious 
dose for the next stage. This design is shown to outperform the corresponding biomarker 
informed two-stage winner design in power. In Chapter 5, we study the concordance 
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between inference decisions made based on interim biomarker and based on study 
primary endpoint in the context of a classical non-small-cell lung cancer trial where a 
regression model linking the interim biomarker (change in tumor size) and primary 
endpoint (survival) exists. It is shown that sample size affects the concordance of 
inference decisions. 
Biomarker informed adaptive clinical trial designs can help prevent certain operational 
challenges, and have the potential to shorten the duration of the trial for drug 
development and avoid unnecessary waste of resources. However, in order to ensure the 
benefits, certain certainty about the surrogacy of the biomarker is required. Therefore, a 
careful consideration is strongly suggested before employing a biomarker informed 
adaptive design. When a good portion of the relationship between the biomarker and the 
primary endpoint is known, the biomarker informed adaptive design is recommended. 
 
In FDA Guidance for Industry about Adaptive Design Clinical Trials for Drugs and 
Biologics,  
 Adaptation of study eligibility criteria based on analyses of pretreatment data 
 Adaptations to maintain study power based on blinded interim analyses of 
aggregate data 
 Adaptations based on interim results of an outcome unrelated to efficacy 
 Adaptations using group sequential methods and unblinded analyses for early 
study termination because of either lack of benefit or demonstrated efficacy 
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 Adaptations in the data analysis plan not dependent on within study, between-
group outcome differences  
are categorized as well-understood adaptive approaches, and can be used in adequate and 
well-controlled (A&WC) studies. 
 Adaptations for dose selection studies 
 Adaptive randomization based on relative treatment group responses 
 Adaptations of sample size based on interim effect size estimates 
 Adaptations of patient population based on treatment-effect estimates 
 Adaptation for endpoint selection based on interim estimate of treatment effect 
 Adaptation of multiple-study design features in a single study 
 Adaptations in non-inferiority studies 
are categorized as less well-understood adaptive approaches, and are encouraged to be 
applied in the exploratory studies to gain more experience. 
It can be seen that, neither of the un-blinded adaptive designs (except the group 
sequential design) is categorized as the well-understood adaptive approach. The 3 major 
concerns by FDA of using an adaptive design in an adequate and well-controlled study 
include: type I error inflation, estimation bias, and operational bias. 
For most of the less well-understood conventional adaptive designs listed above, the 
mathematical framework has been well established. Different statistical methods have 
been proposed in literature to prevent type I error inflation and estimation bias. The 
concerns for these designs are mainly for the operational challenges. 
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However, for the biomarker informed adaptive designs, even the mathematical 
framework has not been fully established yet. Then, is it possible to use a biomarker 
informed adaptive approach in an A&WC study? 
At the end of this dissertation, we describe a scenario where we think the biomarker 
informed adaptive approach might be used in the A&WC study.  
The new trend of making cancer drugs is to develop the combination drugs, that contain a 
marketed drug (denoted by “A”) and an investigational novel drug (denoted by “P”). To 
get a combination drug (denoted by “A P”) approved, besides showing the advantage of 
the combination drug A P over the standard treatment (denoted by “T”) in market, it’s 
also required to show that A+P is better than A in order to demonstrate the added effect 
of novel drug A. It might take too long for the trial to start comparing A+P with T after 
seeing the added effect of P in a phase III trial. The biomarker informed adaptive 
approach might be utilized in this scenario for an early decision about when to start 
recruiting patients for the standard treatment arm T.  
More specifically, start the trial with recruiting patients for the combination drug A+P 
and the marketed drug A, plan an interim look for comparison of the two arms (A+P vs. 
A) on biomarker (e.g. tumor size change). If promising results show on the biomarker, 
start recruiting patients for the standard treatment arm T; otherwise, start recruiting 
patients for the standard treatment arm T until the end of the study when the added effect 
of P is shown.  
In this scenario, the adaptation is used for optimizing the operational procedures, which 
might not undermine the validity and integrity of the clinical trial. 
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APPENDIX A 
R Functions for Calculation of Critical Rejection Values for  
Biomarker Informed Two-Stage Winner Design and  
Biomarker Informed Add-Arm Design for Unimodal Response 
 
library(mnormt) 
 
convention_cv_K4 <- function(w, n1, N, rho, alpha){ 
K=4 
r=rho*sqrt(n1/(2*N)) 
mu=rep(0, K-1) 
varcov=matrix(c(1,r,r,r,2,1,r,1,2),3,3) 
p=(K-1)*sadmvn(lower=c(-18, 0, 0), upper=c(w, 18, 18), mu, varcov) 
error=p[1]-(1-alpha) 
return(list(p=p, error=error)) 
} 
 
convention_cv_K5 <- function(w, n1, N, rho, alpha){ 
K=5 
r=rho*sqrt(n1/(2*N)) 
mu=rep(0, K-1) 
varcov=matrix(c(1,rep(r,4),2,1,1,r,1,2,1, r, 1,1,2),4,4) 
p=(K-1)*sadmvn(lower=c(-18, 0, 0,0), upper=c(w, 18, 18,18), mu, varcov) 
error=p[1]-(1-alpha) 
return(list(p=p, error=error)) 
} 
 
convention_cv_K6 <- function(w, n1, N, rho, alpha){ 
K=6 
r=rho*sqrt(n1/(2*N)) 
mu=rep(0, K-1) 
varcov=matrix(c(1,rep(r,5),2,1,1,1,r,1,2,1,1,r,1,1,2,1,r,1,1,1,2),5,5) 
p=(K-1)*sadmvn(lower=c(-18, 0, 0,0,0), upper=c(w, 18, 18,18,18), mu, varcov) 
error=p[1]-(1-alpha) 
return(list(p=p, error=error)) 
} 
 
convention_cv_K7 <- function(w, n1, N, rho, alpha){ 
K=7 
r=rho*sqrt(n1/(2*N)) 
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mu=rep(0, K-1) 
varcov=matrix(c(1,rep(r,6),2,rep(1,4),r,1,2,rep(1,3),r,1,1,2,1,1,r, rep(1,3),2,1,r, 
rep(1,4),2),6,6) 
p=(K-1)*sadmvn(lower=c(-18, 0, 0,0,0,0), upper=c(w, 18, 18,18,18,18), mu, varcov) 
error=p[1]-(1-alpha) 
return(list(p=p, error=error)) 
} 
 
convention_cv_K8 <- function(w, n1, N, rho, alpha){ 
K=8 
r=rho*sqrt(n1/(2*N)) 
mu=rep(0, K-1) 
varcov=matrix(c(1,rep(r,7),2,rep(1,5),r,1,2,rep(1,4),r,1,1,2,rep(1,3),r, rep(1,3),2,1,1,r, 
rep(1,4),2,1, r, rep(1,5),2),7,7) 
p=(K-1)*sadmvn(lower=c(-18, 0, 0,0,0,0,0), upper=c(w, 18, 18,18,18,18,18), mu, 
varcov) 
error=p[1]-(1-alpha) 
return(list(p=p, error=error)) 
} 
 
wang_cv_K4 <- function(w, n1,N, rho, u0, s2_0,s2_1,s2_2,s2_3,alpha){ 
K=4 
seq_p=c() 
mu=rep(0,K-1) 
s2=c(s2_1,s2_2,s2_3) 
for (j in 1:length(s2)){ 
a=s2[j] 
r=rho*sqrt(n1/N)*sqrt((u0^2*a+1)/(u0^2*a+u0^2*s2_0+2)) 
varcov=matrix(c(1,r,r,r,2,1,r,1,2),3,3) 
p=sadmvn(lower=c(-18, 0, 0), upper=c(w, 18, 18), mu, varcov) 
seq_p=c(seq_p,p[1]) 
} 
total_p=sum(seq_p) 
error=total_p-(1-alpha) 
return(list(p=total_p, error=error)) 
} 
 
wang_cv_K5 <- function(w, n1,N, rho, u0, s2_0,s2_1,s2_2,s2_3,s2_4,alpha){ 
K=5 
seq_p=c() 
mu=rep(0,K-1) 
s2=c(s2_1,s2_2,s2_3,s2_4) 
for (j in 1:length(s2)){ 
a=s2[j] 
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r=rho*sqrt(n1/N)*sqrt((u0^2*a+1)/(u0^2*a+u0^2*s2_0+2)) 
varcov=matrix(c(1,rep(r,4),2,1,1,r,1,2,1, r, 1,1,2),4,4) 
p=sadmvn(lower=c(-18, 0, 0, 0), upper=c(w, 18, 18, 18), mu, varcov) 
seq_p=c(seq_p,p[1]) 
} 
total_p=sum(seq_p) 
error=total_p-(1-alpha) 
return(list(p=total_p, error=error)) 
} 
 
wang_cv_K6 <- function(w, n1,N, rho, u0, s2_0,s2_1,s2_2,s2_3,s2_4,s2_5,alpha){ 
K=6 
seq_p=c() 
mu=rep(0,K-1) 
s2=c(s2_1,s2_2,s2_3,s2_4,s2_5) 
for (j in 1:length(s2)){ 
a=s2[j] 
r=rho*sqrt(n1/N)*sqrt((u0^2*a+1)/(u0^2*a+u0^2*s2_0+2)) 
varcov=matrix(c(1,rep(r,5),2,1,1,1,r,1,2,1,1,r,1,1,2,1,r,1,1,1,2),5,5) 
p=sadmvn(lower=c(-18, 0, 0, 0,0), upper=c(w, 18, 18, 18,18), mu, varcov) 
seq_p=c(seq_p,p[1]) 
} 
total_p=sum(seq_p) 
error=total_p-(1-alpha) 
return(list(p=total_p, error=error)) 
} 
 
wang_cv_K7 <- function(w, n1,N, rho, u0, s2_0,s2_1,s2_2,s2_3,s2_4,s2_5,s2_6,alpha){ 
K=7 
seq_p=c() 
mu=rep(0,K-1) 
s2=c(s2_1,s2_2,s2_3,s2_4,s2_5,s2_6) 
for (j in 1:length(s2)){ 
a=s2[j] 
r=rho*sqrt(n1/N)*sqrt((u0^2*a+1)/(u0^2*a+u0^2*s2_0+2)) 
varcov=matrix(c(1,rep(r,6),2,rep(1,4),r,1,2,rep(1,3),r,1,1,2,1,1,r, rep(1,3),2,1,r, 
rep(1,4),2),6,6) 
p=sadmvn(lower=c(-18, 0, 0, 0,0,0), upper=c(w, 18, 18, 18,18,18), mu, varcov) 
seq_p=c(seq_p,p[1]) 
} 
total_p=sum(seq_p) 
error=total_p-(1-alpha) 
return(list(p=total_p, error=error)) 
} 
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wang_cv_K8 <- function(w, n1,N, rho, u0, 
s2_0,s2_1,s2_2,s2_3,s2_4,s2_5,s2_6,s2_7,alpha){ 
K=8 
seq_p=c() 
mu=rep(0,K-1) 
s2=c(s2_1,s2_2,s2_3,s2_4,s2_5,s2_6,s2_7) 
for (j in 1:length(s2)){ 
a=s2[j] 
r=rho*sqrt(n1/N)*sqrt((u0^2*a+1)/(u0^2*a+u0^2*s2_0+2)) 
varcov=matrix(c(1,rep(r,7),2,rep(1,5),r,1,2,rep(1,4),r,1,1,2,rep(1,3),r, rep(1,3),2,1,1,r, 
rep(1,4),2,1, r, rep(1,5),2),7,7) 
p=sadmvn(lower=c(-18, 0, 0, 0,0,0, 0), upper=c(w, 18, 18, 18,18,18, 18), mu, varcov) 
seq_p=c(seq_p,p[1]) 
} 
total_p=sum(seq_p) 
error=total_p-(1-alpha) 
return(list(p=total_p, error=error)) 
} 
 
addarm_cv_K5 <- function(w, n1=50, N=100, rho, alpha=0.025){ 
K=5 
r=sqrt(n1/N)*rho/2 
mu=rep(0, K-2) 
varcov1=matrix(c(1,0,-r,0, 1, 0.5, -r, 0.5, 1),3,3) 
varcov2=matrix(c(1,r,r, r, 1, 0.5, r, 0.5,1),3,3) 
varcov3=matrix(c(1, -r, r, -r, 1, -0.5, r, -0.5, 1),3,3) 
varcov4=matrix(c(1,0,-r,0, 1, -0.5, -r, -0.5, 1),3,3) 
p=sadmvn(lower=c(-18, 0, -18), upper=c(w, 18, 0.39), mu, varcov1)+sadmvn(lower=c(-
18, 0, 0.39), upper=c(w, 18, 18), mu,  
varcov2)+sadmvn(lower=c(-18, -18, 0.39), upper=c(w, 0, 18), mu, 
varcov3)+sadmvn(lower=c(-18, -18, -18), upper=c(w, 0, 0.39),  
mu, varcov4) 
error=p[1]-(1-alpha) 
return(list(p=p, error=error)) 
} 
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APPENDIX B    
Derivation for     ̂    
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The above equation holds, because an approximation for the variance of ratio proposed in 
Stuart and Ord (1998), 
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APPENDIX C 
Proof of the Equations 
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